Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 686 articles:
HTML format



Single Articles


    June 2022
  1. WANG P, Pan J, Luo Q, Chen J, et al
    A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease.
    Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29127.
    PubMed     Abstract available


  2. STRAKA I, Svantnerova J, Minar M, Stankova S, et al
    Neurodevelopmental Gene-Related Dystonia-Parkinsonism with Onset in Adults: A Case with NAA15 Variant.
    Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29125.
    PubMed    


  3. XIE A, Ensink E, Li P, Gordevicius J, et al
    Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms.
    Mov Disord. 2022 Jun 20. doi: 10.1002/mds.29128.
    PubMed     Abstract available


  4. LUO S, Goetz CG, Choi D, Aggarwal S, et al
    Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.
    Mov Disord. 2022 Jun 18. doi: 10.1002/mds.29129.
    PubMed     Abstract available


  5. COKU I, Mutez E, Eddarkaoui S, Carrier S, et al
    Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
    Mov Disord. 2022 Jun 16. doi: 10.1002/mds.29124.
    PubMed     Abstract available


  6. OLSON JW, Nakhmani A, Irwin ZT, Edwards LJ, et al
    Cortical and Subthalamic Nucleus Spectral Changes During Limb Movements in Parkinson's Disease Patients with and Without Dystonia.
    Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29057.
    PubMed     Abstract available


  7. ATHAUDA D, Evans J, Wernick A, Virdi G, et al
    The Impact of Type 2 Diabetes in Parkinson's Disease.
    Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29122.
    PubMed     Abstract available


  8. AJALIN RM, Al-Abdulrasul H, Tuisku JM, Hirvonen JES, et al
    Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [(18) F]FMPEP-d2.
    Mov Disord. 2022 Jun 8. doi: 10.1002/mds.29117.
    PubMed     Abstract available


  9. RINNE JO, Jucaite A, Cselenyi Z, Farde L, et al
    Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy.
    Mov Disord. 2022 Jun 6. doi: 10.1002/mds.29078.
    PubMed    



  10. The PSG 32nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders.
    Mov Disord. 2022;37 Suppl 1:S1-S36.
    PubMed    


  11. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Reply to: "Risk Disclosure in Prodromal Parkinson's Disease".
    Mov Disord. 2022;37:1327.
    PubMed    


  12. MORRIS LA, O'Callaghan C, Le Heron C
    Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease.
    Mov Disord. 2022;37:1149-1163.
    PubMed     Abstract available


    May 2022
  13. HOBSON DE, Del Bigio MR
    Beekeeper Parkinsonism.
    Mov Disord. 2022 May 31. doi: 10.1002/mds.29076.
    PubMed    


  14. LI C, Hou Y, Ou R, Gu X, et al
    Genetic Determinants of Survival in Parkinson's Disease in the Asian Population.
    Mov Disord. 2022 May 26. doi: 10.1002/mds.29069.
    PubMed     Abstract available


  15. DU G, Wang E, Sica C, Chen H, et al
    Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
    Mov Disord. 2022 May 25. doi: 10.1002/mds.29062.
    PubMed     Abstract available


  16. YANG X, Ai P, He X, Mo C, et al
    Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
    Mov Disord. 2022 May 24. doi: 10.1002/mds.29063.
    PubMed     Abstract available


  17. KIM R, Kim HJ, Shin JH, Lee CY, et al
    Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease.
    Mov Disord. 2022 May 21. doi: 10.1002/mds.29056.
    PubMed     Abstract available


  18. SMEYNE RJ, Eells JB, Chatterjee D, Byrne M, et al
    COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism.
    Mov Disord. 2022 May 17. doi: 10.1002/mds.29116.
    PubMed     Abstract available


  19. YE R, O'Callaghan C, Rua C, Hezemans FH, et al
    Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders.
    Mov Disord. 2022 May 16. doi: 10.1002/mds.29072.
    PubMed     Abstract available


  20. MAHLKNECHT P, Foltynie T, Limousin P, Poewe W, et al
    How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
    Mov Disord. 2022 May 12. doi: 10.1002/mds.29052.
    PubMed     Abstract available


  21. YAMASHITA R, Beck G, Yonenobu Y, Inoue K, et al
    TDP-43 Proteinopathy Presenting with Typical Symptoms of Parkinson's Disease.
    Mov Disord. 2022 May 9. doi: 10.1002/mds.29048.
    PubMed     Abstract available


  22. SOSSI V, Patterson JR, McCormick S, Kemp CJ, et al
    Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease.
    Mov Disord. 2022 May 7. doi: 10.1002/mds.29051.
    PubMed     Abstract available


  23. WANG S, Unnithan S, Bryant N, Chang A, et al
    Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29043.
    PubMed     Abstract available


  24. PAN Y, Xue J, Chen J, Zhang X, et al
    Assessment of GGC Repeat Expansion in GIPC1 in Patients with Parkinson's Disease.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29041.
    PubMed    


  25. FILIPPI M, Balestrino R, Basaia S, Agosta F, et al
    Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29047.
    PubMed     Abstract available


  26. ZHOU X, Liu Z, Zhou X, Xiang Y, et al
    The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics.
    Mov Disord. 2022 May 3. doi: 10.1002/mds.29037.
    PubMed     Abstract available


  27. STEINHARDT J, Hanssen H, Heldmann M, Sprenger A, et al
    Prodromal X-Linked Dystonia-Parkinsonism is Characterized by a Subclinical Motor Phenotype.
    Mov Disord. 2022 May 2. doi: 10.1002/mds.29033.
    PubMed     Abstract available


  28. MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
    Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations".
    Mov Disord. 2022;37:1119-1120.
    PubMed    


  29. GRISANTI S, Ferri L, Cavallieri F, Fioravanti V, et al
    Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Mov Disord. 2022;37:1117-1118.
    PubMed    


  30. LAANSMA MA, Bright JK, Jahanshad N, Thompson PM, et al
    Reply to: "Parkinson's Disease, Premature Mortality, and Amygdala".
    Mov Disord. 2022;37:1111-1112.
    PubMed    


  31. RAO SC, Pattipati S, Salim A, Gutierrez N, et al
    Promoting Gender Inclusivity: A Questionnaire for Women's Health Factors in Parkinson's Disease.
    Mov Disord. 2022;37:1112-1113.
    PubMed    


  32. SCORZA FA, de Almeida AG, Scorza CA, Finsterer J, et al
    Parkinson's Disease, Premature Mortality, and Amygdala.
    Mov Disord. 2022;37:1110-1111.
    PubMed    


  33. DARWEESH SKL, Vermeulen R, Bloem BR, Peters S, et al
    Exposure to Pesticides Predicts Prodromal Feature of Parkinson's Disease: Public Health Implications.
    Mov Disord. 2022;37:883-885.
    PubMed    


  34. SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
    Reply to: "Promoting Gender Inclusivity: A questionnaire for Women's Health Factors in Parkinson's Disease".
    Mov Disord. 2022;37:1113.
    PubMed    


  35. FOFFANI G
    An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2022;37:1105-1106.
    PubMed    


  36. ALZGHOOL OM, van Dongen G, van de Giessen E, Schoonmade L, et al
    alpha-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
    Mov Disord. 2022;37:936-948.
    PubMed     Abstract available


  37. GANAPATHY S R, Levova K, Kotackova L, Trnka J, et al
    Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2022;37:983-992.
    PubMed     Abstract available


  38. TODISCO M, Cosentino G, Scardina S, Fresia M, et al
    Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy.
    Mov Disord. 2022;37:1069-1074.
    PubMed     Abstract available


  39. GAURAV R, Pyatigorskaya N, Biondetti E, Valabregue R, et al
    Deep Learning-Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2022;37:1064-1069.
    PubMed     Abstract available


    April 2022
  40. BANDRES-CIGA S
    Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics.
    Mov Disord. 2022 Apr 30. doi: 10.1002/mds.29042.
    PubMed    


  41. TANIMURA A, Shen W, Wokosin D, Surmeier DJ, et al
    Pathway-Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2022 Apr 29. doi: 10.1002/mds.29030.
    PubMed     Abstract available


  42. KARAGIANIS JL
    Re: Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2022 Apr 28. doi: 10.1002/mds.29038.
    PubMed    


  43. LANGE LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, et al
    Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.
    Mov Disord. 2022 Apr 28. doi: 10.1002/mds.28982.
    PubMed     Abstract available


  44. KOLMANCIC K, Zupancic NK, Trost M, Flisar D, et al
    Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
    Mov Disord. 2022 Apr 18. doi: 10.1002/mds.29028.
    PubMed     Abstract available


  45. YASSINE S, Gschwandtner U, Auffret M, Achard S, et al
    Functional Brain Dysconnectivity in Parkinson's Disease: A 5-Year Longitudinal Study.
    Mov Disord. 2022 Apr 14. doi: 10.1002/mds.29026.
    PubMed     Abstract available


  46. RAMIREZ J, Berberian SA, Breen DP, Gao F, et al
    Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients.
    Mov Disord. 2022 Apr 11. doi: 10.1002/mds.29010.
    PubMed     Abstract available


  47. QUATTRONE A, Bianco MG, Antonini A, Vaillancourt DE, et al
    Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
    Mov Disord. 2022 Apr 11. doi: 10.1002/mds.28992.
    PubMed     Abstract available


  48. UYAR M, Lezius S, Buhmann C, Potter-Nerger M, et al
    Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
    Mov Disord. 2022 Apr 6. doi: 10.1002/mds.29009.
    PubMed     Abstract available


  49. BARBA L, Paolini Paoletti F, Bellomo G, Gaetani L, et al
    Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.
    Mov Disord. 2022;37:669-683.
    PubMed     Abstract available


  50. THIJSSEN E, den Heijer J, Puibert D, Moss L, et al
    A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
    Mov Disord. 2022;37:790-798.
    PubMed     Abstract available


  51. GRIJALVA RM, Pham NTT, Huang Q, Martin PR, et al
    Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2022;37:702-712.
    PubMed     Abstract available


    March 2022
  52. CHOUGAR L, Arsovic E, Gaurav R, Biondetti E, et al
    Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Mov Disord. 2022 Mar 29. doi: 10.1002/mds.28988.
    PubMed     Abstract available


  53. LE HERON C, MacAskill MR, Myall DJ
    Reply to: "An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis".
    Mov Disord. 2022 Mar 28. doi: 10.1002/mds.28989.
    PubMed    


  54. XU Y, Feeney MP, Surface M, Novak D, et al
    Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study.
    Mov Disord. 2022 Mar 26. doi: 10.1002/mds.28990.
    PubMed     Abstract available


  55. SIGURDSSON HP, Yarnall AJ, Galna B, Lord S, et al
    Gait-Related Metabolic Covariance Networks at Rest in Parkinson's Disease.
    Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28977.
    PubMed     Abstract available


  56. NAKANO Y, Hirano S, Kojima K, Li H, et al
    Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders.
    Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28981.
    PubMed     Abstract available


  57. LUAN M, Sun Y, Chen J, Jiang Y, et al
    Diagnostic Value of Salivary Real-Time Quaking-Induced Conversion in Parkinson's Disease and Multiple System Atrophy.
    Mov Disord. 2022 Mar 12. doi: 10.1002/mds.28976.
    PubMed     Abstract available


  58. MURTOMAKI K, Mertsalmi T, Jaakkola E, Makinen E, et al
    Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease.
    Mov Disord. 2022 Mar 11. doi: 10.1002/mds.28986.
    PubMed     Abstract available


  59. STRANIERO L, Rimoldi V, Monfrini E, Bonvegna S, et al
    Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.
    Mov Disord. 2022 Mar 9. doi: 10.1002/mds.28987.
    PubMed     Abstract available


  60. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Erratum to "Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Approach".
    Mov Disord. 2022 Mar 4. doi: 10.1002/mds.28974.
    PubMed    


  61. PRANGE S, Metereau E, Maillet A, Klinger H, et al
    Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease.
    Mov Disord. 2022 Mar 3. doi: 10.1002/mds.28971.
    PubMed     Abstract available


  62. OLSZEWSKA DA, Lang AE
    The Role of Insular Cortex in Gut-Inflammation Memory: What Does It Mean for Parkinson's Disease?
    Mov Disord. 2022 Mar 1. doi: 10.1002/mds.28975.
    PubMed    


  63. LIN CH, Lin HY, Ho EP, Ke YC, et al
    Reply to: Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
    Mov Disord. 2022;37:665-666.
    PubMed    


  64. SAMBIN S, Menon PJ, Ihle J, Mariani LL, et al
    Down-Regulation of Dopamine Transporter in Early Premotor Phases.
    Mov Disord. 2022;37:663-664.
    PubMed    


  65. LINARD M, Ravier A, Mougue L, Grgurina I, et al
    Infectious Agents as Potential Drivers of alpha-Synucleinopathies.
    Mov Disord. 2022;37:464-477.
    PubMed     Abstract available


  66. ROEDIGER J, Dembek TA, Wenzel G, Butenko K, et al
    StimFit-A Data-Driven Algorithm for Automated Deep Brain Stimulation Programming.
    Mov Disord. 2022;37:574-584.
    PubMed     Abstract available


  67. JANZEN A, Kogan RV, Meles SK, Sittig E, et al
    Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern.
    Mov Disord. 2022;37:624-629.
    PubMed     Abstract available


    February 2022
  68. RAO SC, Sanyaolu AO
    Breaking Barriers: Modeling the Blood-Brain Barrier in Parkinson's Disease Using a Human-Brain-Chip.
    Mov Disord. 2022 Feb 28. doi: 10.1002/mds.28968.
    PubMed    


  69. RASCOL O, Medori R, Baayen C, Such P, et al
    A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.
    Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28970.
    PubMed     Abstract available


  70. KHALIL H, Aldaajani ZF, Aldughmi M, Al-Sharman A, et al
    Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28905.
    PubMed     Abstract available


  71. CORNEJO-OLIVAS M, Wu L, Noyce A
    Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism.
    Mov Disord. 2022 Feb 22. doi: 10.1002/mds.28961.
    PubMed    


  72. XING Y, Sapuan AH, Martin-Bastida A, Naidu S, et al
    Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
    Mov Disord. 2022 Feb 15. doi: 10.1002/mds.28934.
    PubMed     Abstract available


  73. LIZARRAGA KJ, Gnanamanogaran B, Al-Ozzi TM, Cohn M, et al
    Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28953.
    PubMed     Abstract available


  74. MAGRINELLI F, Rajapaksha I, Kobylecki C, Latorre A, et al
    Reply to: Juvenile PLA2G6-parkinsonism due to Indian 'Asian' p.R741Q mutation, and response to STN DBS.
    Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28955.
    PubMed    


  75. AYTON S, Hall S, Janelidze S, Kalinowski P, et al
    The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.
    Mov Disord. 2022 Feb 8. doi: 10.1002/mds.28958.
    PubMed     Abstract available


  76. PRASUHN J, Gottlich M, Grosser SS, Reuther K, et al
    In Vivo Brain Sodium Disequilibrium in ATP1A3-Related Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2022 Feb 7. doi: 10.1002/mds.28954.
    PubMed    


  77. MADELUNG CF, Meder D, Fuglsang SA, Marques MM, et al
    Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.
    Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28945.
    PubMed     Abstract available


  78. RAVAT P, Shinde S, Shinde SR, Bangar S, et al
    Juvenile PLA2G6-Parkinsonism Due to Indian 'Asian' p.R741Q Mutation, and Response to STN DBS.
    Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28950.
    PubMed    


  79. SZWEDO AA, Dalen I, Pedersen KF, Camacho M, et al
    GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
    Mov Disord. 2022 Feb 2. doi: 10.1002/mds.28932.
    PubMed     Abstract available


  80. ORTEGA RA, Bodamer O, Peake RWA, Raymond D, et al
    Assessment of Glucocerebrosidase Enzyme Activity in Parkinson Disease Using Multiple Approaches.
    Mov Disord. 2022 Feb 1. doi: 10.1002/mds.28951.
    PubMed    


  81. AAMODT WW, Chen-Plotkin AS
    Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".
    Mov Disord. 2022;37:436-437.
    PubMed    


  82. TODT I, Al-Fatly B, Granert O, Kuhn AA, et al
    The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life.
    Mov Disord. 2022;37:291-301.
    PubMed     Abstract available


  83. D'CRUZ N, Seuthe J, De Somer C, Hulzinga F, et al
    Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait.
    Mov Disord. 2022;37:269-278.
    PubMed     Abstract available


  84. ZIRRA A, Huxford B
    CD4(+) T Cells Contribute to Neurodegeneration in Lewy Body Dementia.
    Mov Disord. 2022;37:268.
    PubMed    


    January 2022
  85. DERKINDEREN P, de Guilhem de Lataillade A, Neunlist M, Rolli-Derkinderen M, et al
    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
    Mov Disord. 2022 Jan 31. doi: 10.1002/mds.28948.
    PubMed    


  86. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease.
    Mov Disord. 2022 Jan 29. doi: 10.1002/mds.28936.
    PubMed    


  87. LIU W, Yu Y
    Single-Trajectory Multiple Target for Parkinsonian Mobility and Cognition? An Inadvisable Idea.
    Mov Disord. 2022 Jan 28. doi: 10.1002/mds.28949.
    PubMed    


  88. GLEASON A, Tayebi N, Lopez G, Sidransky E, et al
    No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.
    Mov Disord. 2022 Jan 24. doi: 10.1002/mds.28935.
    PubMed    


  89. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2022 Jan 22. doi: 10.1002/mds.28929.
    PubMed    


  90. GARRIDO A, Santamaria E, Fernandez-Irigoyen J, Soto M, et al
    Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
    Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28927.
    PubMed     Abstract available


  91. SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
    Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies.
    Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28921.
    PubMed     Abstract available


  92. MURATA H, Barnhill LM, Bronstein JM
    Air Pollution and the Risk of Parkinson's Disease: A Review.
    Mov Disord. 2022 Jan 19. doi: 10.1002/mds.28922.
    PubMed     Abstract available


  93. BUHMANN C, Lezius S, Potter-Nerger M, Gerloff C, et al
    Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD).
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28909.
    PubMed    


  94. COCHEN DE COCK V, Dotov D, Lacombe S, Picot MC, et al
    Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters.
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28894.
    PubMed     Abstract available


  95. VAN DER ZEE S, Kanel P, Gerritsen MJJ, Boertien JM, et al
    Altered Cholinergic Innervation in De Novo Parkinson's Disease with and without Cognitive Impairment.
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28913.
    PubMed     Abstract available


  96. MARTINEZ-VALBUENA I, Visanji NP, Olszewska DA, Sousa M, et al
    Combining Skin alpha-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.
    Mov Disord. 2022 Jan 12. doi: 10.1002/mds.28912.
    PubMed    


  97. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease.
    Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28897.
    PubMed     Abstract available


  98. LEODORI G, De Bartolo MI, Guerra A, Fabbrini A, et al
    Motor Cortical Network Excitability in Parkinson's Disease.
    Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28914.
    PubMed     Abstract available


  99. DOMENIGHETTI C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, et al
    Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.
    Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28902.
    PubMed     Abstract available


  100. VANEGAS-ARROYAVE N, Chen DF, Lauro PM, Norato G, et al
    Where Do Parkinson's Disease Patients Look while Walking?
    Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28917.
    PubMed     Abstract available


  101. MERCHANT K, Sullivan J
    c-Abl Inhibitors as Disease-Modifying Therapies for Parkinson's Disease: Gaps and Opportunities.
    Mov Disord. 2022;37:3-5.
    PubMed    


  102. LA MORGIA C, Romagnoli M, Pizza F, Biscarini F, et al
    Chromatic Pupillometry in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2022;37:205-210.
    PubMed     Abstract available


    December 2021
  103. LEWIS SJG, Factor SA, Giladi N, Hallett M, et al
    Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28837.
    PubMed    


  104. BOHNEN NI, Costa RM, Dauer WT, Factor SA, et al
    Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28883.
    PubMed     Abstract available


  105. GUTTUSO T JR, Sirica D, Tosun D, Zivadinov R, et al
    Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28886.
    PubMed     Abstract available


  106. BOSHKOVSKI T, Cohen-Adad J, Misic B, Arnulf I, et al
    The Myelin-Weighted Connectome in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28891.
    PubMed     Abstract available


  107. DEVIGNES Q, Bordier C, Viard R, Defebvre L, et al
    Resting-State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease-Mild Cognitive Impairment.
    Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28888.
    PubMed     Abstract available


  108. LIN CH, Lin HY, Ho EP, Ke YC, et al
    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-alpha Pathway.
    Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28890.
    PubMed     Abstract available


  109. ZOLFAGHARI S, Thomann AE, Lewandowski N, Trundell D, et al
    Self-Report versus Clinician Examination in Early Parkinson's Disease.
    Mov Disord. 2021 Dec 13. doi: 10.1002/mds.28884.
    PubMed     Abstract available


  110. BRUNO MK, Watanabe G, Ishikawa K, Chen JJ, et al
    Geographic Variation in Prescription Patterns of Parkinson's Disease Medications.
    Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28880.
    PubMed    


  111. RODRIGUEZ-ROJAS R, Pineda-Pardo JA, Manez-Miro J, Sanchez-Turel A, et al
    Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease.
    Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28862.
    PubMed     Abstract available


  112. MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
    Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Mov Disord. 2021 Dec 2. doi: 10.1002/mds.28863.
    PubMed    


  113. GHIGLIERI V, Natale G
    Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
    Mov Disord. 2021;36:2979-2980.
    PubMed    


  114. GARCIA AM, Orozco-Arroyave JR
    Reply to: "Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease".
    Mov Disord. 2021;36:2982-2983.
    PubMed    


  115. RUSZ J, Tykalova T
    Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease?
    Mov Disord. 2021;36:2980-2982.
    PubMed    


  116. SUPPA A
    Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
    Mov Disord. 2021;36:2979.
    PubMed    


  117. YSSELSTEIN D, Young TJ, Nguyen M, Padmanabhan S, et al
    Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.
    Mov Disord. 2021;36:2719-2730.
    PubMed     Abstract available


  118. VERHAGEN METMAN L, Slavin KV, Rosenow JM, Vitek JL, et al
    More Than Just the Level of Consciousness: Comparing Asleep and Awake Deep Brain Stimulation.
    Mov Disord. 2021;36:2763-2766.
    PubMed    


  119. FOIS AF, Mahant N, Vucic S, Fung VSC, et al
    Measuring Tremor-A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating.
    Mov Disord. 2021;36:2962-2963.
    PubMed    


    November 2021
  120. WERNER MH, Olanow CW
    Parkinson's Disease Modification through Abl Kinase Inhibition: An Opportunity.
    Mov Disord. 2021 Nov 23. doi: 10.1002/mds.28858.
    PubMed     Abstract available


  121. SCAMARCIA PG, Agosta F, Spinelli EG, Basaia S, et al
    Longitudinal White Matter Damage Evolution in Parkinson's Disease.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28864.
    PubMed     Abstract available


  122. SASIKUMAR S, Cohn M, Harmsen IE, Loh A, et al
    Single-Trajectory Multiple-Target Deep Brain Stimulation for Parkinsonian Mobility and Cognition.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28870.
    PubMed     Abstract available


  123. CHEN C, Mossman E, Malko P, McDonald D, et al
    Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease.
    Mov Disord. 2021 Nov 15. doi: 10.1002/mds.28849.
    PubMed     Abstract available


  124. COSENTINO C, Torres L, Velez M, Nunez Y, et al
    SARS-CoV-2 Vaccines and Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2021 Nov 14. doi: 10.1002/mds.28851.
    PubMed    


  125. VOGEL A, Claus I, Ahring S, Gruber D, et al
    Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease.
    Mov Disord. 2021 Nov 13. doi: 10.1002/mds.28854.
    PubMed     Abstract available


  126. LANE EL, Harrison DJ, Ramos-Varas E, Hills R, et al
    Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28856.
    PubMed     Abstract available


  127. SURMEIER DJ, Nguyen JT, Lancki N, Venuto CS, et al
    Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28850.
    PubMed     Abstract available


  128. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
    Mov Disord. 2021 Nov 6. doi: 10.1002/mds.28846.
    PubMed     Abstract available


  129. ARPIN DJ, Mitchell T, Archer DB, Burciu RG, et al
    Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
    Mov Disord. 2021 Nov 1. doi: 10.1002/mds.28838.
    PubMed     Abstract available


  130. LESCHZINER AE, Reck-Peterson SL
    Structural Biology of LRRK2 and its Interaction with Microtubules.
    Mov Disord. 2021;36:2494-2504.
    PubMed     Abstract available


  131. MANOR B, Dagan M, Herman T, Gouskova NA, et al
    Multitarget Transcranial Electrical Stimulation for Freezing of Gait: A Randomized Controlled Trial.
    Mov Disord. 2021;36:2693-2698.
    PubMed     Abstract available


  132. LERCHE S, Sjodin S, Brinkmalm A, Blennow K, et al
    CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB.
    Mov Disord. 2021;36:2595-2604.
    PubMed     Abstract available


  133. BORDERS JC, Sevitz JS, Curtis JA, Vanegas-Arroyave N, et al
    Sensorimotor Cough Dysfunction Is Prevalent and Pervasive in Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2624-2633.
    PubMed     Abstract available


    October 2021
  134. CORVOL JC, Azulay JP, Bosse B, Dauvilliers Y, et al
    THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
    Mov Disord. 2021 Oct 28. doi: 10.1002/mds.28840.
    PubMed     Abstract available


  135. CHARISIS S, Ntanasi E, Stamelou M, Xiromerisiou G, et al
    Plasma Glutathione and Prodromal Parkinson's Disease Probability.
    Mov Disord. 2021 Oct 25. doi: 10.1002/mds.28826.
    PubMed     Abstract available


  136. VAN RENSBURG ZJ, Abrahams S, Chetty D, Step K, et al
    The South African Parkinson's Disease Study Collection.
    Mov Disord. 2021 Oct 22. doi: 10.1002/mds.28828.
    PubMed     Abstract available


  137. SAMBIN S, Lavisse S, Decaix C, Pyatigorskaya N, et al
    Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
    Mov Disord. 2021 Oct 20. doi: 10.1002/mds.28833.
    PubMed    


  138. KLARENDIC M, Kirbis M, Mojsovska E, Kavcic M, et al
    Bee Venom Does Not Reduce the Risk for Parkinson's Disease: Epidemiological Study among Beekeepers.
    Mov Disord. 2021 Oct 16. doi: 10.1002/mds.28820.
    PubMed     Abstract available


  139. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Lower Circulating Lymphocyte Count Predicts ApoE epsilon4-Related Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28799.
    PubMed    


  140. HUXFORD B, Haque T, Joseph AB, Simonet C, et al
    Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28829.
    PubMed    


  141. JARAZO J, Barmpa K, Modamio J, Saraiva C, et al
    Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-beta-Cyclodextrin Treatment.
    Mov Disord. 2021 Oct 12. doi: 10.1002/mds.28810.
    PubMed     Abstract available


  142. SCHIRINZI T, Maftei D, Ralli M, Greco A, et al
    Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28824.
    PubMed    


  143. MAGRINELLI F, Mehta S, Di Lazzaro G, Latorre A, et al
    Dissecting the Phenotype and Genotype of PLA2G6-Related Parkinsonism.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28807.
    PubMed     Abstract available


  144. PU JL, Jin CY, Wang ZX, Fang Y, et al
    Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28805.
    PubMed     Abstract available


  145. PIHLSTROM L, Fan CC, Frei O, Tan M, et al
    Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28808.
    PubMed     Abstract available


  146. JUCAITE A, Cselenyi Z, Kreisl WC, Rabiner EA, et al
    Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [(11) C]PBR28 and Machine Learning Analysis.
    Mov Disord. 2021 Oct 5. doi: 10.1002/mds.28814.
    PubMed     Abstract available


  147. GULER S, Gul T, Guler S, Haerle MC, et al
    Early-Onset Parkinson's Disease: A Novel Deletion Comprising the DJ-1 and TNFRSF9 Genes.
    Mov Disord. 2021 Oct 3. doi: 10.1002/mds.28812.
    PubMed     Abstract available


  148. CAMINITI SP, Carli G, Avenali M, Blandini F, et al
    Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.
    Mov Disord. 2021 Oct 1. doi: 10.1002/mds.28818.
    PubMed     Abstract available


  149. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Reply to: "Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population".
    Mov Disord. 2021;36:2453.
    PubMed    


  150. ONG TL, Dal S, Williams LJ, Morales-Briceno H, et al
    \Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021;36:2452.
    PubMed    


  151. GAN-OR Z, Wood NW
    Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?
    Mov Disord. 2021;36:2220-2222.
    PubMed    


  152. NAMBU A
    Distinct Roles of the Dorsal Versus Ventral Subthalamic Nucleus.
    Mov Disord. 2021;36:2223.
    PubMed    


  153. ERRO R, Mencacci NE, Bhatia KP
    The Emerging Role of Phosphodiesterases in Movement Disorders.
    Mov Disord. 2021;36:2225-2243.
    PubMed     Abstract available


  154. CAMACHO M, Greenland JC, Williams-Gray CH
    The Gastrointestinal Dysfunction Scale for Parkinson's Disease.
    Mov Disord. 2021;36:2358-2366.
    PubMed     Abstract available


    September 2021
  155. REYES-PEREZ P, Bandres-Ciga S
    Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication.
    Mov Disord. 2021 Sep 30. doi: 10.1002/mds.28798.
    PubMed    


  156. MILANOWSKI LM, Oshinaike O, Walton RL, Soto-Beasley AI, et al
    Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease.
    Mov Disord. 2021 Sep 29. doi: 10.1002/mds.28803.
    PubMed    


  157. EVIDENTE VGH, Evidente DH, Ortega SC, Levine TD, et al
    X-Linked Dystonia-Parkinsonism ("Lubag") May Present with Peripheral Synucleinopathy.
    Mov Disord. 2021 Sep 28. doi: 10.1002/mds.28801.
    PubMed     Abstract available


  158. REN Y, Jiang H, Pu J, Li L, et al
    Molecular Features of Parkinson's Disease in Patient-Derived Midbrain Dopaminergic Neurons.
    Mov Disord. 2021 Sep 26. doi: 10.1002/mds.28786.
    PubMed     Abstract available


  159. BUCHANAN SM, Richards M, Schott JM, Schrag A, et al
    Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations.
    Mov Disord. 2021 Sep 25. doi: 10.1002/mds.28777.
    PubMed     Abstract available


  160. MAASS F, Michalke B, Willkommen D, Canaslan S, et al
    Cerebrospinal Fluid Iron-Ferritin Ratio as a Potential Progression Marker for Parkinson's Disease.
    Mov Disord. 2021 Sep 23. doi: 10.1002/mds.28790.
    PubMed     Abstract available


  161. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2021 Sep 22. doi: 10.1002/mds.28792.
    PubMed     Abstract available


  162. LAKE J, Reed X, Langston RG, Nalls MA, et al
    Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
    Mov Disord. 2021 Sep 20. doi: 10.1002/mds.28787.
    PubMed     Abstract available


  163. RENNER H, Scholer HR, Bruder JM
    Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28775.
    PubMed     Abstract available


  164. POEWE W, Stocchi F, Arkadir D, Ebersbach G, et al
    Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28758.
    PubMed     Abstract available


  165. MAILLET A, Metereau E, Tremblay L, Favre E, et al
    Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28722.
    PubMed     Abstract available


  166. AAMODT WW, Waligorska T, Shen J, Tropea TF, et al
    Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
    Mov Disord. 2021 Sep 4. doi: 10.1002/mds.28779.
    PubMed     Abstract available


  167. LIN ZH, Zhang BR
    Striking While the Iron is Hot: The Role of Prosaposin (PSAP) in Parkinson's Disease.
    Mov Disord. 2021 Sep 3. doi: 10.1002/mds.28781.
    PubMed    


  168. ELSAYED I, Foote IF
    Improving Diversity in Parkinson's Disease Genetics: Findings from the First-Ever Genome-Wide Association Study in Latinos.
    Mov Disord. 2021 Sep 2. doi: 10.1002/mds.28782.
    PubMed    


  169. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Reply to: "Is Conscientiousness Related to the Risk of Parkinson's Disease?"
    Mov Disord. 2021;36:2216.
    PubMed    


  170. LUCA A, Nicoletti A, Zappia M
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021;36:2215.
    PubMed    


  171. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy".
    Mov Disord. 2021;36:2208-2209.
    PubMed    


  172. LIU H, Koros C, Stefanis L, Gasser T, et al
    Reply to: "alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism".
    Mov Disord. 2021;36:2212-2213.
    PubMed    


  173. RAU A, Jost WH, von der Warth R, Urbach H, et al
    Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2207-2208.
    PubMed    


  174. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Parkinson's Disease.
    Mov Disord. 2021;36:2217.
    PubMed    


  175. SOKRATOUS M, Breza M, Senkevich K, Gan-Or Z, et al
    alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism.
    Mov Disord. 2021;36:2209-2212.
    PubMed    


  176. ISHIMOTO T, Yamakado H
    Membranes and Organelle in Lewy Bodies: The Mastermind or the Bystander?
    Mov Disord. 2021;36:2026.
    PubMed    


  177. MAJBOUR NK, Abdi IY, Dakna M, Wicke T, et al
    Cerebrospinal alpha-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Mov Disord. 2021;36:2048-2056.
    PubMed     Abstract available


  178. ANDERSEN KB, Hansen AK, Damholdt MF, Horsager J, et al
    Reduced Synaptic Density in Patients with Lewy Body Dementia: An [(11) C]UCB-J PET Imaging Study.
    Mov Disord. 2021;36:2057-2065.
    PubMed     Abstract available


    August 2021
  179. LIU Y, Lawton MA, Lo C, Bowring F, et al
    Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study.
    Mov Disord. 2021 Aug 26. doi: 10.1002/mds.28763.
    PubMed     Abstract available


  180. KAINAGA M, Shirota Y, Kodama S, Toda T, et al
    Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson's Disease: An Observational Study.
    Mov Disord. 2021 Aug 25. doi: 10.1002/mds.28766.
    PubMed    


  181. ONOFRJ M, Di Iorio A, Carrarini C, Russo M, et al
    Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease.
    Mov Disord. 2021 Aug 24. doi: 10.1002/mds.28745.
    PubMed     Abstract available


  182. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach.
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28760.
    PubMed     Abstract available


  183. CAMPESE N, Goebel G, Leys F, Ndayisaba JP, et al
    Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28768.
    PubMed    


  184. O'SHEA SA, Hickman RA, Cortes E, Vonsattel JP, et al
    Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1.
    Mov Disord. 2021 Aug 20. doi: 10.1002/mds.28756.
    PubMed     Abstract available


  185. CIRNARU MD, Creus-Muncunill J, Nelson S, Lewis T, et al
    Striatal Cholinergic Dysregulation after Neonatal Decrease in X-Linked Dystonia Parkinsonism-Related TAF1 Isoforms.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28750.
    PubMed     Abstract available


  186. SIA MW, Foo JN, Saffari SE, Wong AS, et al
    Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28761.
    PubMed     Abstract available


  187. QI S, Yin P, Wang L, Qu M, et al
    Prevalence of Parkinson's Disease: A Community-Based Study in China.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28762.
    PubMed     Abstract available


  188. GARCIA AM, Arias-Vergara T, C Vasquez-Correa J, Noth E, et al
    Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28751.
    PubMed     Abstract available


  189. LE HERON C, MacAskill M, Mason D, Dalrymple-Alford J, et al
    A Multi-Step Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2021 Aug 10. doi: 10.1002/mds.28719.
    PubMed     Abstract available


  190. ERRO R, Buonomo AR, Barone P, Pellecchia MT, et al
    Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson Disease.
    Mov Disord. 2021 Aug 9. doi: 10.1002/mds.28772.
    PubMed    


  191. OLANOW CW, Poewe W, Rascol O, Stocchi F, et al
    On-Demand Therapy for OFF Episodes in Parkinson's Disease.
    Mov Disord. 2021 Aug 7. doi: 10.1002/mds.28726.
    PubMed     Abstract available


  192. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28723.
    PubMed     Abstract available


  193. OKUNOYE O, Horsfall L, Marston L, Walters K, et al
    Mortality of People with Parkinson's Disease in a Large UK-Based Cohort Study: Time Trends and Relationship to Disease Duration.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28727.
    PubMed     Abstract available


  194. MARKAKI I, Ntetsika T, Svenningsson P
    Reply to: "HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study".
    Mov Disord. 2021;36:1993.
    PubMed    


  195. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Reply to: Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994-1995.
    PubMed    


  196. TORRES L, Velez M, Suarez R, Nunez Y, et al
    Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994.
    PubMed    


  197. ZITTEL S, Uyar M, Lezius S, Gerloff C, et al
    HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study.
    Mov Disord. 2021;36:1991-1992.
    PubMed    


  198. ZECH M, Jech R, Boesch S, Skorvanek M, et al
    Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.
    Mov Disord. 2021;36:1959-1964.
    PubMed     Abstract available


  199. KOSS DJ, Campesan S, Giorgini F, Outeiro TF, et al
    Dysfunction of RAB39B-Mediated Vesicular Trafficking in Lewy Body Diseases.
    Mov Disord. 2021;36:1744-1758.
    PubMed     Abstract available


  200. FASANO A, Gurevich T, Jech R, Kovacs N, et al
    Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
    Mov Disord. 2021;36:1853-1862.
    PubMed     Abstract available


  201. KIM R, Lee JY, Kim YK, Kim H, et al
    Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder-Related Metabolic Pattern Expression.
    Mov Disord. 2021;36:1889-1898.
    PubMed     Abstract available


    July 2021
  202. REN X, Lin J, Stebbins GT, Goetz CG, et al
    Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.
    Mov Disord. 2021 Jul 30. doi: 10.1002/mds.28730.
    PubMed     Abstract available


  203. LAANSMA MA, Bright JK, Al-Bachari S, Anderson TJ, et al
    International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
    Mov Disord. 2021 Jul 20. doi: 10.1002/mds.28706.
    PubMed     Abstract available


  204. SARASSO E, Agosta F, Piramide N, Gardoni A, et al
    Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study.
    Mov Disord. 2021 Jul 19. doi: 10.1002/mds.28717.
    PubMed     Abstract available


  205. GROS P, Wang X, Guan J, Lang AE, et al
    Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.
    Mov Disord. 2021 Jul 9. doi: 10.1002/mds.28712.
    PubMed     Abstract available


  206. CONCHA-MARAMBIO L, Farris CM, Holguin B, Ma Y, et al
    Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28715.
    PubMed    


  207. FREIRE-ALVAREZ E, Kurca E, Lopez Manzanares L, Pekkonen E, et al
    Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28703.
    PubMed     Abstract available


  208. MULLER-NEDEBOCK AC, Komolafe MA, Fawale MB, Carr JA, et al
    Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa.
    Mov Disord. 2021 Jul 6. doi: 10.1002/mds.28710.
    PubMed    


  209. SCHILLING M, Lill CM
    MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression.
    Mov Disord. 2021 Jul 5. doi: 10.1002/mds.28700.
    PubMed    


  210. CHOONG CJ, Kimura Y, Mochizuki H
    Disturbed Mitochondria-Lysosome Crosstalk in GBA1-Associated Parkinson's Disease.
    Mov Disord. 2021 Jul 1. doi: 10.1002/mds.28693.
    PubMed    


  211. RASCOL O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, et al
    Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
    Mov Disord. 2021;36:1704-1711.
    PubMed     Abstract available


  212. SHILL HA, Zhang N, Driver-Dunckley E, Mehta S, et al
    Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:1700-1704.
    PubMed     Abstract available


  213. PERKINS JE, Janzen A, Bernhard FP, Wilhelm K, et al
    Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1720-1726.
    PubMed     Abstract available


  214. DE ALMEIDA CMO, Brito MMC, Bosaipo NB, Pimentel AV, et al
    Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1711-1715.
    PubMed     Abstract available


  215. WITTKE C, Petkovic S, Dobricic V, Schaake S, et al
    Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
    Mov Disord. 2021;36:1499-1510.
    PubMed     Abstract available


    June 2021
  216. VIDENOVIC A, Amara AW, Comella C, Schweitzer PK, et al
    Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Mov Disord. 2021 Jun 30. doi: 10.1002/mds.28702.
    PubMed     Abstract available


  217. PATEL SG, Buchanan CM, Mulroy E, Simpson M, et al
    Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.
    Mov Disord. 2021 Jun 22. doi: 10.1002/mds.28665.
    PubMed    


  218. FIORENZATO E, Antonini A, Bisiacchi P, Weis L, et al
    Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Jun 14. doi: 10.1002/mds.28682.
    PubMed     Abstract available


  219. NIGAM M, Ayadi I, Noiray C, Branquino-Bras AC, et al
    Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28692.
    PubMed     Abstract available


  220. GELPI E, Haberler C, Micko A, Polt A, et al
    Focal Subthalamic Atrophy After Long-Term Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28653.
    PubMed    


  221. MAITI B, Rawson KS, Tanenbaum AB, Koller JM, et al
    Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease.
    Mov Disord. 2021 Jun 10. doi: 10.1002/mds.28684.
    PubMed     Abstract available


  222. MUNOZ-DELGADO L, Macias-Garcia D, Jesus S, Martin-Rodriguez JF, et al
    Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease.
    Mov Disord. 2021 Jun 8. doi: 10.1002/mds.28685.
    PubMed     Abstract available


  223. SEGER AD, Farrher E, Doppler CEJ, Gogishvili A, et al
    Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
    Mov Disord. 2021 Jun 7. doi: 10.1002/mds.28674.
    PubMed     Abstract available


  224. HAMID E, Ayele BA, Massi DG, Ben Sassi S, et al
    Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
    Mov Disord. 2021 Jun 3. doi: 10.1002/mds.28669.
    PubMed     Abstract available


  225. ISONAKA R, Goldstein DS, Zhu W, Yoon E, et al
    alpha-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
    Mov Disord. 2021 Jun 2. doi: 10.1002/mds.28667.
    PubMed     Abstract available


  226. MATHUR S
    Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients.
    Mov Disord. 2021;36:1290-1292.
    PubMed    


    May 2021
  227. CARVALHO V, Ferreira JJ, Correia Guedes L
    Tremor and Parkinsonism in Chromosomopathies - A Systematic Review.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28663.
    PubMed     Abstract available


  228. CONEYS R, Storm CS, Kia DA, Almramhi M, et al
    Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28662.
    PubMed     Abstract available


  229. FEARON C, Mikulis DJ, Lang AE
    Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28656.
    PubMed    


  230. BOUALI-BENAZZOUZ R, Benazzouz A
    Covid-19 Infection and Parkinsonism: Is There a Link?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28680.
    PubMed     Abstract available


  231. ORSO B, Arnaldi D, Girtler N, Brugnolo A, et al
    Dopaminergic and Serotonergic Degeneration and Cortical [(18) F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28654.
    PubMed     Abstract available


  232. DEAN DN, Lee JC
    Linking Parkinson's Disease and Melanoma: Interplay Between alpha-Synuclein and Pmel17 Amyloid Formation.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28655.
    PubMed     Abstract available


  233. SCHWEDHELM E, Englisch C, Niemann L, Lezius S, et al
    Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD).
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28652.
    PubMed     Abstract available


  234. TOFFOLI M, Higgins A, Lee C, Koletsi S, et al
    Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28616.
    PubMed     Abstract available


  235. STUENDL A, Kraus T, Chatterjee M, Zapke B, et al
    alpha-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28639.
    PubMed     Abstract available


  236. O'SULLIVAN JM, den Heijer JM, Groeneveld GJ, Cooper AA, et al
    Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28620.
    PubMed    


  237. HAN F, Brown GL, Zhu Y, Belkin-Rosen AE, et al
    Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
    Mov Disord. 2021 May 17. doi: 10.1002/mds.28643.
    PubMed     Abstract available


  238. MORLEY D, Dummett S, Kelly L, Jenkinson C, et al
    Development of an Exercise-Specific Parkinson's Disease Questionnaire: The PDQ-Exercise.
    Mov Disord. 2021 May 15. doi: 10.1002/mds.28644.
    PubMed     Abstract available


  239. MARRAS C, Mills KA, Eberly S, Oakes D, et al
    Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients With Early Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28641.
    PubMed     Abstract available


  240. RICCIARDI L, Fischer P, Mostofi A, Tinkhauser G, et al
    Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28625.
    PubMed     Abstract available


  241. ESTIAR MA, Senkevich K, Yu E, Varghaei P, et al
    Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28640.
    PubMed     Abstract available


  242. COLLOBY SJ, Nathan PJ, Bakker G, Lawson RA, et al
    Spatial Covariance of Cholinergic Muscarinic M1 /M4 Receptors in Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28564.
    PubMed     Abstract available


  243. NAITO T, Satake W, Ogawa K, Suzuki K, et al
    Trans-Ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28583.
    PubMed     Abstract available


  244. BARBUTI PA, Barker RA, Brundin P, Przedborski S, et al
    Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
    Mov Disord. 2021 May 8. doi: 10.1002/mds.28628.
    PubMed     Abstract available


  245. IWAKI H, Leonard HL, Makarious MB, Bookman M, et al
    Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28549.
    PubMed     Abstract available


  246. DI LAZZARO G, Magrinelli F, Estevez-Fraga C, Valente EM, et al
    X-Linked Parkinsonism: Phenotypic and Genetic Heterogeneity.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28565.
    PubMed     Abstract available


  247. MCINTOSH E, Kent S, Gray A, Clarke CE, et al
    Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28623.
    PubMed     Abstract available


  248. MIRELMAN A, Ben Or Frank M, Melamed M, Granovsky L, et al
    Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28631.
    PubMed     Abstract available


  249. KAASINEN V, Vahlberg T, Stoessl AJ, Strafella AP, et al
    Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28632.
    PubMed     Abstract available


  250. KREMER T, Taylor KI, Siebourg-Polster J, Gerken T, et al
    Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28608.
    PubMed     Abstract available


  251. SCHERBAUM R, Kwon EH, Richter D, Bartig D, et al
    Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28586.
    PubMed     Abstract available


  252. MESTRE TA, Macklin EA, Ascherio A, Ferreira JJ, et al
    Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28630.
    PubMed     Abstract available


  253. SCOTT GD, Lim MM, Drake MG, Woltjer R, et al
    Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans.
    Mov Disord. 2021 May 3. doi: 10.1002/mds.28636.
    PubMed     Abstract available


  254. KIEBURTZ K, Olanow CW
    Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".
    Mov Disord. 2021;36:1281-1282.
    PubMed    


  255. SIMON DK
    A New Approach to the Development of Disease-Modifying Therapies for PD.
    Mov Disord. 2021;36:1281.
    PubMed    


  256. LERCHE S, Schulte C, Wurster I, Machetanz G, et al
    The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA.
    Mov Disord. 2021;36:1216-1228.
    PubMed     Abstract available


    April 2021
  257. YILMAZ R, Suenkel U, Postuma RB, Heinzel S, et al
    Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies.
    Mov Disord. 2021 Apr 30. doi: 10.1002/mds.28637.
    PubMed    


  258. SARANZA G, Villanueva EQ 3rd, Lang AE
    Preferences for Communication About End-of-Life Care in Atypical Parkinsonism.
    Mov Disord. 2021 Apr 28. doi: 10.1002/mds.28633.
    PubMed     Abstract available


  259. HUYNH B, Fu Y, Kirik D, Shine JM, et al
    Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
    Mov Disord. 2021 Apr 26. doi: 10.1002/mds.28615.
    PubMed     Abstract available


  260. TSUNEMI T, Oyama G, Saiki S, Hatano T, et al
    Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Mov Disord. 2021 Apr 25. doi: 10.1002/mds.28595.
    PubMed     Abstract available


  261. LETA V, Rodriguez-Violante M, Abundes A, Rukavina K, et al
    Parkinson's disease and Post-COVID-19 syndrome: The Parkinson's Long-COVID spectrum.
    Mov Disord. 2021 Apr 22. doi: 10.1002/mds.28622.
    PubMed    


  262. LI C, Ou R, Chen Y, Gu X, et al
    Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study.
    Mov Disord. 2021 Apr 21. doi: 10.1002/mds.28621.
    PubMed     Abstract available


  263. CHEN Y, Wu W, Zhao S, Lv X, et al
    Increased Accumulation of alpha-Synuclein in Inflamed Appendices of Parkinson's Disease Patients.
    Mov Disord. 2021 Apr 20. doi: 10.1002/mds.28553.
    PubMed     Abstract available


  264. JOHNSON LA, Aman JE, Yu Y, Escobar Sanabria D, et al
    High-Frequency Oscillations in the Pallidum: A Pathophysiological Biomarker in Parkinson's Disease?
    Mov Disord. 2021 Apr 13. doi: 10.1002/mds.28566.
    PubMed     Abstract available


  265. SOARES C, Carneiro DR, Dias R, Ferreira D, et al
    Behind the mask: recognizing facial features of Parkinson's disease during the COVID-19 pandemic.
    Mov Disord. 2021 Apr 9. doi: 10.1002/mds.28619.
    PubMed    


  266. ZAHED H, Zuzuarregui JRP, Gilron R, Denison T, et al
    The Neurophysiology of Sleep in Parkinson's Disease.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28562.
    PubMed     Abstract available


  267. LIM SH, Ferdousi M, Kalteniece A, Mahfoud ZR, et al
    Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28602.
    PubMed     Abstract available


  268. JIANG C, Hopfner F, Berg D, Hu MT, et al
    Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28591.
    PubMed     Abstract available


  269. KOOHI N, Bancroft MJ, Patel J, Castro P, et al
    Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations.
    Mov Disord. 2021 Apr 6. doi: 10.1002/mds.28609.
    PubMed    


  270. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28575.
    PubMed     Abstract available


  271. UEDA J, Uemura N, Sawamura M, Taguchi T, et al
    Perampanel Inhibits alpha-Synuclein Transmission in Parkinson's Disease Models.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28558.
    PubMed     Abstract available


  272. NIJHUIS FAP, Esselink R, de Bie RMA, Groenewoud H, et al
    Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
    Mov Disord. 2021 Apr 2. doi: 10.1002/mds.28599.
    PubMed     Abstract available


  273. HELMICH RC, Van den Berg KRE, Panyakaew P, Cho HJ, et al
    Cerebello-Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease.
    Mov Disord. 2021 Apr 1. doi: 10.1002/mds.28603.
    PubMed    


  274. GUTTLER C, Nikulin VV, van Riesen C
    Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
    Mov Disord. 2021;36:1045-1047.
    PubMed    


  275. SCHMIDT SL, Grill WM
    Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2021;36:1044-1045.
    PubMed    


  276. NEUMANN WJ, Rodriguez-Oroz MC
    Machine Learning Will Extend the Clinical Utility of Adaptive Deep Brain Stimulation.
    Mov Disord. 2021;36:796-799.
    PubMed    


  277. RUSZ J, Tykalova T, Ramig LO, Tripoliti E, et al
    Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders.
    Mov Disord. 2021;36:803-814.
    PubMed     Abstract available


  278. GEORGIEV D, Roskar S, Cus A, Wilkinson L, et al
    STN-DBS Increases Proactive but Not Retroactive Interference During Verbal Learning in PD.
    Mov Disord. 2021;36:1010-1015.
    PubMed     Abstract available


  279. OSHIMA S, Fushimi Y, Okada T, Nakajima S, et al
    Neuromelanin-Sensitive Magnetic Resonance Imaging Using DANTE Pulse.
    Mov Disord. 2021;36:874-882.
    PubMed     Abstract available


  280. BOOTH S, Ramadan A, Zhang D, Lu L, et al
    The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
    Mov Disord. 2021;36:938-947.
    PubMed     Abstract available


    March 2021
  281. VISANJI NP, Lang AE
    Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28590.
    PubMed    


  282. KLUGER BM, Dolhun R, Sumrall M, Hall K, et al
    Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28556.
    PubMed    


  283. SCHIESS M, Suescun J, Doursout MF, Adams C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
    Mov Disord. 2021 Mar 27. doi: 10.1002/mds.28582.
    PubMed     Abstract available


  284. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021 Mar 25. doi: 10.1002/mds.28594.
    PubMed     Abstract available


  285. GROVER S, Kumar-Sreelatha AA, Bobbili DR, May P, et al
    Replication of a Novel Parkinson's Locus in a European Ancestry Population.
    Mov Disord. 2021 Mar 24. doi: 10.1002/mds.28546.
    PubMed     Abstract available


  286. ABRAHAM DS, Pham Nguyen TP, Willis AW
    Claims-Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease.
    Mov Disord. 2021 Mar 23. doi: 10.1002/mds.28561.
    PubMed     Abstract available


  287. YAO CW, Saha-Chaudhuri P, Zolfaghari S, Pelletier A, et al
    Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population-Based CLSA.
    Mov Disord. 2021 Mar 22. doi: 10.1002/mds.28571.
    PubMed    


  288. SALARI M, Etemadifar M, Zali A, Medghalchi A, et al
    Seroprevalence of SARS-CoV-2 in Parkinson's Disease Patients: A Case-Control Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28580.
    PubMed    


  289. MARINI K, Seppi K, Tschiderer L, Kiechl S, et al
    Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28570.
    PubMed    


  290. CANONICO M, Pesce G, Bonaventure A, Le Noan-Laine M, et al
    Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy.
    Mov Disord. 2021 Mar 16. doi: 10.1002/mds.28563.
    PubMed     Abstract available


  291. DOBKIN RD, Mann SL, Weintraub D, Rodriguez KM, et al
    Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment.
    Mov Disord. 2021 Mar 12. doi: 10.1002/mds.28548.
    PubMed     Abstract available


  292. GAURAV R, Yahia-Cherif L, Pyatigorskaya N, Mangone G, et al
    Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Mov Disord. 2021 Mar 10. doi: 10.1002/mds.28531.
    PubMed     Abstract available


  293. CHOHAN H, Senkevich K, Patel RK, Bestwick JP, et al
    Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
    Mov Disord. 2021 Mar 8. doi: 10.1002/mds.28551.
    PubMed     Abstract available


  294. DUYSENS J, Nonnekes J
    Parkinson's Kinesia Paradoxa Is Not a Paradox.
    Mov Disord. 2021 Mar 3. doi: 10.1002/mds.28550.
    PubMed    


  295. CLAUS I, Muhle P, Czechowski J, Ahring S, et al
    Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease.
    Mov Disord. 2021 Mar 2. doi: 10.1002/mds.28552.
    PubMed     Abstract available


  296. FEARON C, Lang AE, Espay AJ
    The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes.
    Mov Disord. 2021;36:594-598.
    PubMed    


  297. BORGHAMMER P, Horsager J
    The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes.
    Mov Disord. 2021;36:785-786.
    PubMed    


  298. FEARON C, Lang AE, J Espay A
    Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes".
    Mov Disord. 2021;36:786-787.
    PubMed    


  299. SARTER M, Avila C, Kucinski A, Donovan E, et al
    Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.
    Mov Disord. 2021;36:535-546.
    PubMed     Abstract available


  300. YOUNCE JR, Campbell MC, Hershey T, Tanenbaum AB, et al
    Resting-State Functional Connectivity Predicts STN DBS Clinical Response.
    Mov Disord. 2021;36:662-671.
    PubMed     Abstract available


  301. POLISSIDIS A, Koronaiou M, Kollia V, Koronaiou E, et al
    Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human alpha-Synuclein BAC Transgenic Rats.
    Mov Disord. 2021;36:716-728.
    PubMed     Abstract available


  302. HANSS Z, Larsen SB, Antony P, Mencke P, et al
    Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
    Mov Disord. 2021;36:704-715.
    PubMed     Abstract available


    February 2021
  303. DE MICCO R, Agosta F, Basaia S, Siciliano M, et al
    Functional Connectomics and Disease Progression in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28541.
    PubMed     Abstract available


  304. BURTSCHER J, Syed MMK, Lashuel HA, Millet GP, et al
    Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28544.
    PubMed     Abstract available


  305. MARKAKI I, Ntetsika T, Sorjonen K, Svenningsson P, et al
    Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28545.
    PubMed     Abstract available


  306. CHAHINE LM, Zhu X, Ehrenkranz R, Chen H, et al
    Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28535.
    PubMed    


  307. KAKAR RS, Pastor JV, Moe OW, Ambrosio F, et al
    Peripheral Klotho and Parkinson's Disease.
    Mov Disord. 2021 Feb 25. doi: 10.1002/mds.28530.
    PubMed    


  308. MOONEN AJH, Mulders AEP, Defebvre L, Duits A, et al
    Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28533.
    PubMed     Abstract available


  309. AVENALI M, Cerri S, Ongari G, Ghezzi C, et al
    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28496.
    PubMed     Abstract available


  310. LIU H, Koros C, Strohaker T, Schulte C, et al
    A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28534.
    PubMed     Abstract available


  311. SONG S, Luo Z, Li C, Huang X, et al
    Changes in Body Composition Before and After Parkinson's Disease Diagnosis.
    Mov Disord. 2021 Feb 22:e28536. doi: 10.1002/mds.28536.
    PubMed     Abstract available


  312. AEED F, Cermak N, Schiller J, Schiller Y, et al
    Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2021 Feb 19. doi: 10.1002/mds.28538.
    PubMed     Abstract available


  313. KLEINER G, Fernandez HH, Chou KL, Fasano A, et al
    Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire.
    Mov Disord. 2021 Feb 15. doi: 10.1002/mds.28507.
    PubMed     Abstract available


  314. GALPER J, Balwani M, Fahn S, Waters C, et al
    Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers With and Without Parkinson Disease.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28525.
    PubMed     Abstract available


  315. BRIGHT JM, Carlisle HJ, Toda AMA, Murphy M, et al
    Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28490.
    PubMed     Abstract available


  316. PAZ RM, Tubert C, Stahl AM, Amarillo Y, et al
    Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
    Mov Disord. 2021 Feb 6. doi: 10.1002/mds.28516.
    PubMed     Abstract available


  317. ANTAR T, Iwaki H, B Singleton A
    Reply to: 'Letter to the Editor on "Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities"'.
    Mov Disord. 2021;36:527-528.
    PubMed    


  318. OUTEIRO TF, Krisko A
    Reply to: "Parkinson's Disease and COVID-19: Do We Need to Be More Patient?"
    Mov Disord. 2021;36:278-279.
    PubMed    


  319. GONZALEZ-LATAPI P, Fearon C, Fasano A, Lang AE, et al
    Parkinson's Disease and COVID-19: Do We Need to Be More Patient?
    Mov Disord. 2021;36:277.
    PubMed    


  320. DE LA ROSA T, Amado Scerni D, Scorza FA
    Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities.
    Mov Disord. 2021;36:526.
    PubMed    


  321. HO GPH, Ramalingam N, Imberdis T, Wilkie EC, et al
    Upregulation of Cellular Palmitoylation Mitigates alpha-Synuclein Accumulation and Neurotoxicity.
    Mov Disord. 2021;36:348-359.
    PubMed     Abstract available


    January 2021
  322. MULLER-NEDEBOCK AC, van der Westhuizen FH, Koks S, Bardien S, et al
    Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28475.
    PubMed     Abstract available


  323. JEONG SH, Lee HS, Jung JH, Baik K, et al
    White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28510.
    PubMed     Abstract available



  324. GP2: The Global Parkinson's Genetics Program.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28494.
    PubMed    


  325. KIM JJ, Makarious MB, Bandres-Ciga S, Gibbs JR, et al
    The Parkinson's Disease DNA Variant Browser.
    Mov Disord. 2021 Jan 26. doi: 10.1002/mds.28488.
    PubMed     Abstract available


  326. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28462.
    PubMed     Abstract available


  327. DONAHUE EK, Murdos A, Jakowec MW, Sheikh-Bahaei N, et al
    Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28473.
    PubMed     Abstract available


  328. WELTON T, Tan EK
    Applying Artificial Intelligence to Multi-Omic Data: New Functional Variants in Parkinson's Disease.
    Mov Disord. 2021 Jan 17. doi: 10.1002/mds.28481.
    PubMed    


  329. MICHELI F, Vissani M, Pecchioli G, Terenzi F, et al
    Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity.
    Mov Disord. 2021 Jan 16. doi: 10.1002/mds.28497.
    PubMed     Abstract available


  330. AVRAM CM, Brumbach BH, Hiller AL
    A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28471.
    PubMed     Abstract available


  331. LIN CH, Chang CH, Tai CH, Cheng MF, et al
    A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28474.
    PubMed     Abstract available


  332. RAVANIDIS S, Bougea A, Karampatsi D, Papagiannakis N, et al
    Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 12. doi: 10.1002/mds.28467.
    PubMed     Abstract available


  333. HERZ DM, Meder D, Camilleri JA, Eickhoff SB, et al
    Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28468.
    PubMed     Abstract available


  334. VILA-VICOSA D, Clemente A, Pona-Ferreira F, Leitao M, et al
    Unsupervised walking activity assessment reveals COVID-19 impact on Parkinson's disease patients.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28514.
    PubMed    


  335. ZARKALI A, McColgan P, Leyland LA, Lees AJ, et al
    Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
    Mov Disord. 2021 Jan 9. doi: 10.1002/mds.28477.
    PubMed     Abstract available


  336. KUUSIMAKI T, Al-Abdulrasul H, Kurki S, Hietala J, et al
    Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28484.
    PubMed     Abstract available


  337. CHEN L, Bedard P, Hallett M, Horovitz SG, et al
    Dynamics of Top-Down Control and Motor Networks in Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28461.
    PubMed     Abstract available


  338. SCHIRINZI T, Maftei D, Pieri M, Bernardini S, et al
    Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28458.
    PubMed    


  339. METCALFE-ROACH A, Yu AC, Golz E, Cirstea M, et al
    MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28464.
    PubMed     Abstract available


  340. BAUMGARTNER AJ, Press DZ, Simon DK
    The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28483.
    PubMed    


  341. CHOE CU, Potter-Nerger M, Buhmann C, Blankenberg S, et al
    Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease".
    Mov Disord. 2021;36:273-274.
    PubMed    


  342. TRILCK-WINKLER M, Borsche M, Konig IR, Balck A, et al
    Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
    Mov Disord. 2021;36:271-273.
    PubMed    


  343. WITT K
    The Impact of the Basal Ganglia on Working Memory: Evidence from Parkinson's Disease.
    Mov Disord. 2021;36:13-15.
    PubMed    


  344. FULLER RLM, Sanchez-Ferro A, Goetz CG, Martinez-Martin P, et al
    In Support of Electronic Versions of Movement Disorder Society Rating Scales.
    Mov Disord. 2021;36:270-271.
    PubMed    


  345. TURNER TH, Dale ML
    Reply to: "In Support of Electronic Versions of Movement Disorder Society Rating Scales".
    Mov Disord. 2021;36:271.
    PubMed    


  346. SARANZA G, Lang AE
    Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
    Mov Disord. 2021;36:265-266.
    PubMed    


  347. KIEBURTZ K, Katz R, McGarry A, Olanow CW, et al
    A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
    Mov Disord. 2021;36:59-63.
    PubMed     Abstract available


  348. VIEIRA-YANO B, Martini DN, Horak FB, de Lima-Pardini A, et al
    The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity.
    Mov Disord. 2021;36:152-163.
    PubMed     Abstract available


    December 2020
  349. WILSON J, Yarnall AJ, Craig CE, Galna B, et al
    Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Mov Disord. 2020 Dec 31. doi: 10.1002/mds.28453.
    PubMed     Abstract available


  350. DUITS AA, Boots LMM, Mulders AEP, Moonen AJH, et al
    Covid Proof Self-Management Training for Caregivers of Patients with Parkinson's Disease.
    Mov Disord. 2020 Dec 27. doi: 10.1002/mds.28457.
    PubMed    


  351. FILIPPOU P, Outeiro TF
    Cancer and Parkinson's Disease: Common Targets, Emerging Hopes.
    Mov Disord. 2020 Dec 21. doi: 10.1002/mds.28425.
    PubMed     Abstract available


  352. NISSEN SK, Ferreira SA, Nielsen MC, Schulte C, et al
    Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
    Mov Disord. 2020 Dec 17. doi: 10.1002/mds.28424.
    PubMed     Abstract available


  353. ZOON TJC, van Rooijen G, Balm GMFC, Bergfeld IO, et al
    Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2020 Dec 16. doi: 10.1002/mds.28390.
    PubMed     Abstract available


  354. SKRAHINA V, Gaber H, Vollstedt EJ, Forster TM, et al
    The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28416.
    PubMed     Abstract available


  355. KLINE EM, Houser MC, Herrick MK, Seibler P, et al
    Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28411.
    PubMed     Abstract available


  356. ELFIL M, Bahbah EI, Attia MM, Eldokmak M, et al
    Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease.
    Mov Disord. 2020 Dec 9. doi: 10.1002/mds.28412.
    PubMed     Abstract available


  357. MULLIN S, Stokholm MG, Hughes D, Mehta A, et al
    Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.
    Mov Disord. 2020 Dec 5. doi: 10.1002/mds.28375.
    PubMed     Abstract available


  358. CAREY G, Gormezoglu M, de Jong JJA, Hofman PAM, et al
    Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2020 Dec 2. doi: 10.1002/mds.28404.
    PubMed     Abstract available


  359. OLSZEWSKA DA, Lang AE
    "Opening" New Insights Into LRRK2 Conformation and the Microtubule.
    Mov Disord. 2020;35:2162-2163.
    PubMed    


    November 2020
  360. MARTIN WRW, Miles M, Zhong Q, Hartlein J, et al
    Is Levodopa Response a Valid Indicator of Parkinson's Disease?
    Mov Disord. 2020 Nov 30. doi: 10.1002/mds.28406.
    PubMed     Abstract available


  361. GUTTLER C, Altschuler J, Tanev K, Bockmann S, et al
    Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2020 Nov 28. doi: 10.1002/mds.28403.
    PubMed     Abstract available


  362. PORTLEY MK, Scholz SW
    Hot Topic: Epigenetics in Parkinson's Disease: A New Frontier for Disease-Modifying Therapies.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28410.
    PubMed    


  363. SANTOS-GARCIA D, Pozojevic J, de Deus Fonticoba T, Kurtis M, et al
    First Case of Parkinsonian-Pyramidal Syndrome Associated with a TBK1 Mutation.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28405.
    PubMed    


  364. WALDTHALER J, Stock L, Sommerkorn J, Kruger-Zechlin C, et al
    Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease.
    Mov Disord. 2020 Nov 25. doi: 10.1002/mds.28374.
    PubMed    


  365. AL-QASSABI A, Tsao TS, Racolta A, Kremer T, et al
    Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28399.
    PubMed     Abstract available


  366. JAAKKOLA E, Huovinen A, Kaasinen V, Joutsa J, et al
    No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28400.
    PubMed    


  367. GARCIA-SANZ P, M F G Aerts J, Moratalla R
    The Role of Cholesterol in alpha-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease.
    Mov Disord. 2020 Nov 21. doi: 10.1002/mds.28396.
    PubMed     Abstract available


  368. PAGAN FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, et al
    Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
    Mov Disord. 2020 Nov 20. doi: 10.1002/mds.28389.
    PubMed     Abstract available


  369. ERREA O, Rodriguez-Oroz MC
    Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease.
    Mov Disord. 2020 Nov 18. doi: 10.1002/mds.28393.
    PubMed    


  370. OJUKWU DI, Andruska KM, Halpern CH
    Lessons From George Floyd: Racial Inequalities in the Treatment of Parkinson's Disease.
    Mov Disord. 2020 Nov 17. doi: 10.1002/mds.28388.
    PubMed    


  371. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28378.
    PubMed    


  372. OUTEIRO TF, Heutink P, Bezard E, Cenci AM, et al
    From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28387.
    PubMed     Abstract available


  373. VIGNATELLI L, Zenesini C, Belotti LMB, Baldin E, et al
    Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28408.
    PubMed     Abstract available


  374. MAETZLER W, Rochester L, Bhidayasiri R, Espay AJ, et al
    Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures.
    Mov Disord. 2020 Nov 15. doi: 10.1002/mds.28377.
    PubMed     Abstract available


  375. DEVOS D, Hirsch E, Wyse R
    Seven Solutions for Neuroprotection in Parkinson's Disease.
    Mov Disord. 2020 Nov 13. doi: 10.1002/mds.28379.
    PubMed     Abstract available


  376. DE MICCO R, Satolli S, Siciliano M, Di Nardo F, et al
    Connectivity Correlates of Anxiety Symptoms in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 10. doi: 10.1002/mds.28372.
    PubMed     Abstract available


  377. PICILLO M, Phokaewvarangkul O, Poon YY, McIntyre CC, et al
    Levodopa Versus Dopamine Agonist After Subthalamic Stimulation in Parkinson's Disease.
    Mov Disord. 2020 Nov 9. doi: 10.1002/mds.28382.
    PubMed     Abstract available


  378. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28364.
    PubMed     Abstract available


  379. SARIHAN EI, Perez-Palma E, Niestroj LM, Loesch D, et al
    Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28353.
    PubMed     Abstract available


  380. VAN DER ZEE S, Muller MLTM, Kanel P, van Laar T, et al
    Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28360.
    PubMed     Abstract available


  381. CHOUGAR L, Faouzi J, Pyatigorskaya N, Yahia-Cherif L, et al
    Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28348.
    PubMed     Abstract available


  382. DORSEY ER, Bloem BR, Okun MS
    A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.
    Mov Disord. 2020;35:1897-1902.
    PubMed     Abstract available


  383. HERRINGTON TM, Schweitzer J, Henchcliffe C, Carter BS, et al
    Toward a Personalized Approach to Parkinson's Cell Therapy.
    Mov Disord. 2020;35:2119-2120.
    PubMed    


  384. SILVA-BATISTA C, M Corcos D, B Horak F, Ugrinowitsch C, et al
    Reply to: 'Letter to the Editor on "A Randomized Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait"'.
    Mov Disord. 2020;35:2123-2124.
    PubMed    


  385. KORDOWER JH, Okun MS, Jankovic J
    Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy".
    Mov Disord. 2020;35:2120-2121.
    PubMed    


  386. NONNEKES J, Gilat M, D'Cruz N, Dijkstra BW, et al
    Letter to the Editor on "A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait".
    Mov Disord. 2020;35:2122-2123.
    PubMed    


    October 2020
  387. TAN MMX, Lawton MA, Jabbari E, Reynolds RH, et al
    Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2020 Oct 28. doi: 10.1002/mds.28342.
    PubMed     Abstract available


  388. SUN YM, Yu HL, Zhou XY, Xiong WX, et al
    Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28349.
    PubMed     Abstract available


  389. MENOZZI E, Macnaughtan J, Schapira AHV
    LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28347.
    PubMed    


  390. VAN DEN HEUVEL L, Evers L, Meinders M, Post B, et al
    Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28339.
    PubMed     Abstract available


  391. BEYLERGIL SB, Petersen M, Gupta P, Elkasaby M, et al
    Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading.
    Mov Disord. 2020 Oct 26. doi: 10.1002/mds.28352.
    PubMed     Abstract available


  392. YE Z, Zhang G, Zhang Y, Li S, et al
    The Role of the Subthalamic Nucleus in Sequential Working Memory in De Novo Parkinson's Disease.
    Mov Disord. 2020 Oct 24. doi: 10.1002/mds.28344.
    PubMed     Abstract available


  393. VAN DER HEIDE A, Meinders MJ, Speckens AEM, Peerbolte TF, et al
    Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms.
    Mov Disord. 2020 Oct 23. doi: 10.1002/mds.28345.
    PubMed     Abstract available


  394. FU JF, Matarazzo M, McKenzie J, Neilson N, et al
    Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
    Mov Disord. 2020 Oct 22. doi: 10.1002/mds.28340.
    PubMed     Abstract available


  395. YIN W, Lof M, Pedersen NL, Sandin S, et al
    Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study.
    Mov Disord. 2020 Oct 20. doi: 10.1002/mds.28314.
    PubMed     Abstract available


  396. TAKEDA A, Takahashi R, Tsuboi Y, Nomoto M, et al
    Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations.
    Mov Disord. 2020 Oct 19. doi: 10.1002/mds.28322.
    PubMed     Abstract available


  397. LOWES H, Robertson F, Pyle A, Hussain R, et al
    The human coronavirus receptor ANPEP (CD13) is overexpressed in Parkinson's disease.
    Mov Disord. 2020 Oct 18. doi: 10.1002/mds.28354.
    PubMed    


  398. SCHLOSSMACHER MG, Graybiel AM
    Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28316.
    PubMed     Abstract available


  399. TAKAMIYA A, Seki M, Kudo S, Yoshizaki T, et al
    Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28335.
    PubMed     Abstract available


  400. MESTRE TA, Kessler D, Cote D, Liddy C, et al
    Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28332.
    PubMed     Abstract available


  401. BELVISI D, Fabbrini A, De Bartolo MI, Costanzo M, et al
    The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes.
    Mov Disord. 2020 Oct 10. doi: 10.1002/mds.28321.
    PubMed     Abstract available


  402. DAHODWALA N, Li P, Jahnke J, Ladage VP, et al
    Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
    Mov Disord. 2020 Oct 8. doi: 10.1002/mds.28265.
    PubMed     Abstract available


  403. SANTIN MDN, Voulleminot P, Vrillon A, Hainque E, et al
    Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2020 Oct 6. doi: 10.1002/mds.28320.
    PubMed     Abstract available


  404. ISRAEL Z, Asch N
    Reversing a Model of Parkinson's Disease With In Situ Converted Nigral Neurons.
    Mov Disord. 2020 Oct 5. doi: 10.1002/mds.28306.
    PubMed    


  405. BONVEGNA S, Straccia G, Golfre Andreasi N, Elia AE, et al
    Parkinsonism and Nigrostriatal Damage Secondary to CSF1R-Related Primary Microgliopathy.
    Mov Disord. 2020 Oct 3. doi: 10.1002/mds.28290.
    PubMed    


  406. KANE PB, Benjamin DM, Barker RA, Lang AE, et al
    Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28319.
    PubMed     Abstract available


  407. TSUBOI T, Charbel M, Peterside DT, Rana M, et al
    Pallidal Connectivity Profiling of Stimulation-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28324.
    PubMed     Abstract available


  408. IWAKI H, Blauwendraat C, Leonard HL, Makarious MB, et al
    Differences in the Presentation and Progression of Parkinson's Disease by Sex.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28312.
    PubMed     Abstract available


  409. MUFTI K, Rudakou U, Yu E, Krohn L, et al
    Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28318.
    PubMed     Abstract available


  410. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Reply to: "Can the 2019 Novel Coronavirus Cause Parkinson's Disease?"
    Mov Disord. 2020;35:1726.
    PubMed    


  411. HURWITZ B, Lees AJ, Walusinski O
    Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease.
    Mov Disord. 2020;35:1880-1881.
    PubMed    


  412. SULLIVAN R, Yau WY, Chelban V, Rossi S, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1890-1891.
    PubMed    


  413. DA SILVA SCHMITT G, Martinez ARM, da Graca FF, de Lima FD, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1889-1890.
    PubMed    


  414. AGUIRRE-PADILLA DH, Lozano AM, Fasano A
    Reply to: "Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?"
    Mov Disord. 2020;35:1883.
    PubMed    


  415. MONTGOMERY EB JR
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020;35:1891.
    PubMed    


  416. CURY RG, Carra RB, Capato TTC, Teixeira MJ, et al
    Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?
    Mov Disord. 2020;35:1882-1883.
    PubMed    


  417. MONJE MHG, Martinez-Fernandez R
    Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?
    Mov Disord. 2020;35:1725.
    PubMed    


  418. ALVES M, Caldeira D, Reimao S, Ferro JM, et al
    N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease.
    Mov Disord. 2020;35:1886-1887.
    PubMed    


  419. CHOE CU, Petersen E, Potter-Nerger M, Buhmann C, et al
    Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease".
    Mov Disord. 2020;35:1888.
    PubMed    


  420. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease".
    Mov Disord. 2020;35:1882.
    PubMed    


  421. CROTTY GF, Lo RY, Schwarzschild MA
    If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?
    Mov Disord. 2020;35:1727-1730.
    PubMed    


    September 2020
  422. BLUMENREICH S, Jenkins BJ, Barav OB, Milenkovic I, et al
    The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28232.
    PubMed    


  423. RAJPUT AH, Kish SJ
    Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28317.
    PubMed    


  424. AL ALI J, Vaine CA, Shah S, Campion L, et al
    TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 25. doi: 10.1002/mds.28305.
    PubMed     Abstract available


  425. YU E, Rudakou U, Krohn L, Mufti K, et al
    Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease.
    Mov Disord. 2020 Sep 24. doi: 10.1002/mds.28299.
    PubMed     Abstract available


  426. DOMMERSHUIJSEN LJ, Heshmatollah A, Mattace Raso FUS, Koudstaal PJ, et al
    Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
    Mov Disord. 2020 Sep 23. doi: 10.1002/mds.28303.
    PubMed     Abstract available


  427. MANNE S, Kondru N, Jin H, Serrano GE, et al
    Blinded RT-QuIC Analysis of alpha-Synuclein Biomarker in Skin Tissue from Parkinson's Disease Patients.
    Mov Disord. 2020 Sep 22. doi: 10.1002/mds.28242.
    PubMed     Abstract available


  428. DIAW SH, Lohmann K
    Linking Huntington's Disease and X-Linked Dystonia Parkinsonism on the Molecular Level.
    Mov Disord. 2020 Sep 22. doi: 10.1002/mds.28287.
    PubMed    


  429. TERROBA-CHAMBI C, Abulafia C, Vigo DE, Merello M, et al
    Heart Rate Variability and Mild Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Sep 21. doi: 10.1002/mds.28234.
    PubMed    


  430. ZHANG Q, Schultz JL, Aldridge GM, Simmering JE, et al
    COVID-19 case fatality and Parkinson's disease.
    Mov Disord. 2020 Sep 21. doi: 10.1002/mds.28325.
    PubMed    


  431. PAULY MG, Ruiz Lopez M, Westenberger A, Saranza G, et al
    Expanding Data Collection for the MDSGene Database: X-Linked Dystonia-Parkinsonism as Use Case Example.
    Mov Disord. 2020 Sep 19. doi: 10.1002/mds.28289.
    PubMed     Abstract available


  432. FLORIN E, Koschmieder KC, Schnitzler A, Becker S, et al
    Recovery of Impaired Endogenous Pain Modulation by Dopaminergic Medication in Parkinson's Disease.
    Mov Disord. 2020 Sep 18. doi: 10.1002/mds.28241.
    PubMed     Abstract available


  433. KRISMER F, Beliveau V, Seppi K, Mueller C, et al
    Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease.
    Mov Disord. 2020 Sep 16. doi: 10.1002/mds.28281.
    PubMed     Abstract available


  434. JUNG JH, Kim BH, Chung SJ, Yoo HS, et al
    Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease.
    Mov Disord. 2020 Sep 14. doi: 10.1002/mds.28243.
    PubMed     Abstract available


  435. TANTAWY AAG, Adly AAM, Hashem NH, Ebeid WM, et al
    Ganglion Cell Complex Thinning in Young Gaucher Patients: Relation to Prodromal Parkinsonian Markers.
    Mov Disord. 2020 Sep 12. doi: 10.1002/mds.28256.
    PubMed     Abstract available


  436. PERINAN MT, Macias-Garcia D, Labrador-Espinosa MA, Jesus S, et al
    Association of PICALM with Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Sep 11. doi: 10.1002/mds.28283.
    PubMed     Abstract available


  437. REIMAO S, Guerreiro C, Seppi K, Ferreira JJ, et al
    A Standardized MR Imaging Protocol for Parkinsonism.
    Mov Disord. 2020 Sep 11. doi: 10.1002/mds.28204.
    PubMed    


  438. KOGAN RV, Janzen A, Meles SK, Sittig E, et al
    Four-Year Follow-up of [(18) F]Fluorodeoxyglucose Positron Emission Tomography-Based Parkinson's Disease-Related Pattern Expression in 20 Patients With Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression.
    Mov Disord. 2020 Sep 10. doi: 10.1002/mds.28260.
    PubMed     Abstract available


  439. KRAUSE C, Schaake S, Grutz K, Sievert H, et al
    DNA Methylation as a Potential Molecular Mechanism in X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 10. doi: 10.1002/mds.28239.
    PubMed     Abstract available


  440. LI C, Ou R, Chen Y, Gu X, et al
    ATP10B and the Risk for Early-Onset Parkinson's Disease.
    Mov Disord. 2020 Sep 9. doi: 10.1002/mds.28285.
    PubMed    


  441. MELLO LGM, Bissoli LB, Saraiva FP, Maia RPD, et al
    Retinal Layers and Choroid Measurements in Parkinson's Disease with or Without Pramipexole Treatment.
    Mov Disord. 2020 Sep 9. doi: 10.1002/mds.28280.
    PubMed    


  442. TAN AH, Lim SY, Mahadeva S, Loke MF, et al
    Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial.
    Mov Disord. 2020 Sep 7. doi: 10.1002/mds.28248.
    PubMed     Abstract available


  443. FILIPPI M, Canu E, Donzuso G, Stojkovic T, et al
    Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2020 Sep 4. doi: 10.1002/mds.28228.
    PubMed     Abstract available


  444. SIPILA JOT, Kaasinen V
    No Change in the Age-Adjusted Incidence of Parkinson's Disease in Finland for More Than 25 Years.
    Mov Disord. 2020 Sep 2. doi: 10.1002/mds.28250.
    PubMed    


  445. CHEN SJ, Kuo CH, Kuo HC, Chen CC, et al
    The Gut Metabolite Trimethylamine N-Oxide Is Associated With Parkinson's Disease Severity and Progression.
    Mov Disord. 2020 Sep 2. doi: 10.1002/mds.28246.
    PubMed    


  446. ZHANG X
    Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease".
    Mov Disord. 2020;35:1695.
    PubMed    


  447. LU C, Amundsen Huffmaster SL, Louie KH, Sovell-Brown K, et al
    Pallidal Oscillation Dynamics Following Cessation of Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2020;35:1697-1698.
    PubMed    


  448. SPEECKAERT MM, Speeckaert R, Delanghe JR
    Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1497.
    PubMed    


  449. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Reply to: 'Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease"'.
    Mov Disord. 2020;35:1695-1697.
    PubMed    


  450. NEUMANN WJ, Feldmann L, Kuhn AA
    Reply to: Pallidal Low-Frequency Activity in Dystonia and Subthalamic Beta Activity in Parkinson's Disease.
    Mov Disord. 2020;35:1699.
    PubMed    


  451. CEREDA E, Fasano A, Pezzoli G
    Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1498.
    PubMed    


  452. WEIL RS
    Visual Dysfunction and Parkinson's Disease.
    Mov Disord. 2020;35:1499-1501.
    PubMed    


    August 2020
  453. SGAMBATO V
    Blood Flow as a Route for Bidirectional Propagation of Synucleinopathy in Parkinson's Disease?
    Mov Disord. 2020 Aug 31. doi: 10.1002/mds.28236.
    PubMed    


  454. GRENN FP, Kim JJ, Makarious MB, Iwaki H, et al
    The Parkinson's Disease Genome-Wide Association Study Locus Browser.
    Mov Disord. 2020 Aug 31. doi: 10.1002/mds.28197.
    PubMed     Abstract available


  455. CHEONG JLY, Goh ZHK, Marras C, Tanner CM, et al
    The impact of COVID-19 on access to Parkinson's disease medication.
    Mov Disord. 2020 Aug 28. doi: 10.1002/mds.28293.
    PubMed     Abstract available


  456. GREUEL A, Trezzi JP, Glaab E, Ruppert MC, et al
    GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes.
    Mov Disord. 2020 Aug 27. doi: 10.1002/mds.28225.
    PubMed     Abstract available


  457. STUART S, Morris R, Giritharan A, Quinn J, et al
    Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy.
    Mov Disord. 2020 Aug 24. doi: 10.1002/mds.28214.
    PubMed     Abstract available


  458. FOLLMER C
    Gut Microbiome Imbalance and Neuroinflammation: Impact of COVID-19 on Parkinson's Disease.
    Mov Disord. 2020 Aug 21. doi: 10.1002/mds.28231.
    PubMed    


  459. OLANOW CW, Calabresi P, Obeso JA
    Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities.
    Mov Disord. 2020 Aug 20. doi: 10.1002/mds.28215.
    PubMed     Abstract available


  460. FABER I, Brandao PRP, Menegatti F, Bispo DDC, et al
    Covid-19 and Parkinsonism: A non-post-encephalitic case.
    Mov Disord. 2020 Aug 19. doi: 10.1002/mds.28277.
    PubMed    


  461. MOLLENHAUER B, Dakna M, Kruse N, Galasko D, et al
    Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28206.
    PubMed     Abstract available


  462. MARKAKI I, Bergstrom S, Tsitsi P, Remnestal J, et al
    Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28192.
    PubMed     Abstract available


  463. PALERMO G, Tommasini L, Baldacci F, Del Prete E, et al
    Impact of COVID-19 pandemic on cognition in Parkinson's disease.
    Mov Disord. 2020 Aug 10. doi: 10.1002/mds.28254.
    PubMed    


  464. SANTOS GARCIA D, Oreiro M, Perez P, Fanjul G, et al
    Impact of COVID-19 Pandemic on Parkinson s Disease: A Cross-sectional Survey of 568 Spanish Patients.
    Mov Disord. 2020 Aug 10. doi: 10.1002/mds.28261.
    PubMed     Abstract available


  465. DELVA A, Van Weehaeghe D, Koole M, Van Laere K, et al
    Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease.
    Mov Disord. 2020 Aug 7. doi: 10.1002/mds.28216.
    PubMed     Abstract available


  466. BALESTRINO R, Tunesi S, Tesei S, Lopiano L, et al
    Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: a Kin Cohort Study.
    Mov Disord. 2020 Aug 7. doi: 10.1002/mds.28200.
    PubMed     Abstract available


  467. CHOI JH, Lee JY, Cho JW, Koh SB, et al
    Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study.
    Mov Disord. 2020 Aug 6. doi: 10.1002/mds.28219.
    PubMed     Abstract available


  468. DELLI PIZZI S, Franciotti R, Ferretti A, Edden RAE, et al
    High gamma-Aminobutyric Acid Content within the Medial Prefrontal Cortex Is a Functional Signature of Somatic Symptoms Disorder in Patients with Parkinson's Disease.
    Mov Disord. 2020 Aug 3. doi: 10.1002/mds.28221.
    PubMed     Abstract available


  469. ANTONINI A, Leta V, Teo J, Ray Chaudhuri K, et al
    Reply to: "Concerns Raised by Publication of Antonini et al., 'Outcome of Parkinson Disease Patients Affected by Covid-19'".
    Mov Disord. 2020;35:1298.
    PubMed    


  470. RAPHAEL KG
    Concerns Raised by Publication of Antonini et al., "Outcome of Parkinson Disease Patients Affected by Covid-19".
    Mov Disord. 2020;35:1297.
    PubMed    


    July 2020
  471. WEINTRAUB D, Chiang C, Kim HM, Wilkinson J, et al
    Clinical Follow-up of Parkinson's Disease With Newly Prescribed Quetiapine.
    Mov Disord. 2020 Jul 29. doi: 10.1002/mds.28193.
    PubMed    


  472. BHARAT V, Wang X
    Precision Neurology for Parkinson's Disease: Coupling Miro1-Based Diagnosis with Drug Discovery.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28194.
    PubMed     Abstract available


  473. HEILMAN PL, Wang EW, Lewis MM, Krzyzanowski S, et al
    Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28202.
    PubMed     Abstract available


  474. HAN G, Han J, Han K, Youn J, et al
    Visual Acuity and Development of Parkinson's Disease: A Nationwide Cohort Study.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28184.
    PubMed     Abstract available


  475. CHEN Y, Gu X, Ou R, Zhang L, et al
    Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
    Mov Disord. 2020 Jul 16. doi: 10.1002/mds.28191.
    PubMed     Abstract available


  476. LI C, Ou R, Chen Y, Gu X, et al
    Mutation Analysis of DNAJC Family for Early-Onset Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28203.
    PubMed     Abstract available


  477. SAN LUCIANO M, Tanner CM, Meng C, Marras C, et al
    Nonsteroidal Anti-Inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28189.
    PubMed     Abstract available


  478. HAMEDANI AG, Abraham DS, Maguire MG, Willis AW, et al
    Visual Impairment Is More Common in Parkinson's Disease and Is a Risk Factor for Poor Health Outcomes.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28182.
    PubMed     Abstract available


  479. PETRUCCI S, Ginevrino M, Trezzi I, Monfrini E, et al
    GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort.
    Mov Disord. 2020 Jul 13. doi: 10.1002/mds.28195.
    PubMed     Abstract available


  480. MESTRE TA, Freitas E, Basndwah A, Lopez MR, et al
    Glycopyrrolate Improves Disability from Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial.
    Mov Disord. 2020 Jul 13. doi: 10.1002/mds.28196.
    PubMed     Abstract available


  481. KLATT-SCHREINER K, Valek L, Kang JS, Khlebtovsky A, et al
    High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease.
    Mov Disord. 2020 Jul 11. doi: 10.1002/mds.28186.
    PubMed     Abstract available


  482. DE FRANCESCO E, Terzaghi M, Storelli E, Magistrelli L, et al
    CD4+ T-Cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2020 Jul 10. doi: 10.1002/mds.28137.
    PubMed     Abstract available


  483. YING AF, Khan S, Wu Y, Jin A, et al
    Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study.
    Mov Disord. 2020 Jul 9. doi: 10.1002/mds.28173.
    PubMed     Abstract available


  484. PARKER JE, Martinez A, Deutsch GK, Prabhakar V, et al
    Safety of Plasma Infusions in Parkinson's Disease.
    Mov Disord. 2020 Jul 7. doi: 10.1002/mds.28198.
    PubMed     Abstract available


  485. DEN HEIJER JM, Cullen VC, Quadri M, Schmitz A, et al
    A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.
    Mov Disord. 2020 Jul 2. doi: 10.1002/mds.28112.
    PubMed     Abstract available


  486. ZETTERBERG H
    Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease?
    Mov Disord. 2020;35:1111-1112.
    PubMed    


  487. MACASKILL MR, Myall DJ, Shoorangiz R, Anderson TJ, et al
    Childbirth and Delayed Parkinson's Onset: A Reproducible Nonbiological Artifact of Societal Change.
    Mov Disord. 2020;35:1268-1271.
    PubMed     Abstract available


  488. CERRONI R, Pierantozzi M, Moleti A, Stefani A, et al
    Laterality of Auditory Dysfunction in Parkinson's Disease.
    Mov Disord. 2020;35:1283-1284.
    PubMed    


  489. POPAT RA, Nelson LM
    What Matters in Parkinson's Disease: Sex, Number of Children, or Birth Cohort?
    Mov Disord. 2020;35:1108-1110.
    PubMed    


  490. FRANGE C, Huebra Pimentel Filho L, Aguilar AC, Coelho FMS, et al
    Exercise for "Sleep Rehabilitation" in Parkinson's Disease.
    Mov Disord. 2020;35:1285.
    PubMed    


  491. AMARA AW, Wood KH, Joop A, Memon RA, et al
    Reply to: Exercise for "Sleep Rehabilitation" in Parkinson's Disease.
    Mov Disord. 2020;35:1286.
    PubMed    


  492. JAFARI Z, Kolb BE, Mohajerani MH
    Reply to a Letter by Dr. Stefani and Colleagues on: "Auditory Dysfunction in Parkinson's Disease".
    Mov Disord. 2020;35:1284-1285.
    PubMed    


  493. LERCHE S, Wurster I, Roben B, Zimmermann M, et al
    CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Mov Disord. 2020;35:1138-1144.
    PubMed     Abstract available


    June 2020
  494. AZIZ NA, Roos RAC, Pijl H
    Insulin Sensitivity in De Novo Parkinson's Disease: A Hyperinsulinemic-Euglycemic Clamp Study.
    Mov Disord. 2020 Jun 30. doi: 10.1002/mds.28181.
    PubMed    


  495. RAJAN R, Brennan L, Bloem BR, Dahodwala N, et al
    Integrated Care in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Jun 29. doi: 10.1002/mds.28097.
    PubMed     Abstract available


  496. KOBYLECKI C, Jones T, Lim CK, Miller C, et al
    Phenomenology and outcomes of in-patients with Parkinson's disease during COVID-19 pandemic.
    Mov Disord. 2020 Jun 24. doi: 10.1002/mds.28205.
    PubMed    


  497. RAMIREZ J, Dilliott AA, Binns MA, Breen DP, et al
    Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities.
    Mov Disord. 2020 Jun 23. doi: 10.1002/mds.28171.
    PubMed     Abstract available


  498. GIAGKOU N, Maraki MI, Yannakoulia M, Kosmidis MH, et al
    A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease.
    Mov Disord. 2020 Jun 22. doi: 10.1002/mds.28145.
    PubMed     Abstract available


  499. OJO OO, Abubakar SA, Iwuozo EU, Nwazor EO, et al
    The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a Collaborative Project.
    Mov Disord. 2020 Jun 19. doi: 10.1002/mds.28123.
    PubMed     Abstract available


  500. KOULI A, Williams-Gray CH
    Timing Is Everything: The T-Cell Response to alpha-Synuclein Is Maximal in Early Parkinson's.
    Mov Disord. 2020 Jun 19. doi: 10.1002/mds.28122.
    PubMed    


  501. SILVA-BATISTA C, de Lima-Pardini AC, Nucci MP, Coelho DB, et al
    A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28128.
    PubMed     Abstract available


  502. NISHIWAKI H, Ito M, Ishida T, Hamaguchi T, et al
    Meta-Analysis of Gut Dysbiosis in Parkinson's Disease.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28119.
    PubMed     Abstract available


  503. DONADIO V, Incensi A, Rizzo G, De Micco R, et al
    Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease with Orthostatic Hypotension.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28126.
    PubMed     Abstract available


  504. SCHIERDING W, Farrow S, Fadason T, Graham OEE, et al
    Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28144.
    PubMed     Abstract available


  505. CHOE CU, Niemann L, Englisch C, Petersen E, et al
    Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease.
    Mov Disord. 2020 Jun 17. doi: 10.1002/mds.28129.
    PubMed     Abstract available


  506. JANKOVIC J, Okun MS, Kordower JH
    Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease.
    Mov Disord. 2020 Jun 12. doi: 10.1002/mds.28187.
    PubMed    


  507. PURRI R, Brennan L, Rick J, Xie SX, et al
    Subjective Cognitive Complaint in Parkinson's Disease Patients with Normal Cognition: Canary in the Coal Mine?
    Mov Disord. 2020 Jun 10. doi: 10.1002/mds.28115.
    PubMed     Abstract available


  508. AIT WAHMANE S, Achbani A, Ouhaz Z, Elatiqi M, et al
    The possible protective role of alpha-synuclein against the SARS-CoV-2 infections in patients with Parkinson's disease.
    Mov Disord. 2020 Jun 9. doi: 10.1002/mds.28185.
    PubMed    


  509. HATTORI N, Kitabayashi H, Kanda T, Nomura T, et al
    A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease.
    Mov Disord. 2020 Jun 5. doi: 10.1002/mds.28095.
    PubMed     Abstract available


  510. MARINI K, Mahlknecht P, Tutzer F, Stockner H, et al
    Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort.
    Mov Disord. 2020 Jun 3. doi: 10.1002/mds.28127.
    PubMed     Abstract available


  511. VALE TC, Barbosa MT, Franca Resende EP, Silva LC, et al
    No Correlation Between White Matter Changes and Mild Parkinsonian Signs in Individuals Aged Older Than 75 Years.
    Mov Disord. 2020 Jun 3. doi: 10.1002/mds.28120.
    PubMed    


  512. FASANO A, Cereda E, Barichella M, Cassani E, et al
    COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy.
    Mov Disord. 2020 Jun 2. doi: 10.1002/mds.28176.
    PubMed     Abstract available


  513. POSTUMA RB
    Exercise and Sleep in Parkinson's Disease.
    Mov Disord. 2020;35:918-920.
    PubMed    


  514. MARTINEZ-FERNANDEZ R
    Letter to the Editor: "Subthalamic Nucleus Stimulation Impairs Motivation: Implication for Apathy in Parkinson's Disease".
    Mov Disord. 2020;35:1084.
    PubMed    


  515. GOETZ CG, Stebbins GT, Luo S
    Movement Disorder Society-Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era.
    Mov Disord. 2020;35:911.
    PubMed    


  516. VACHEZ Y, Carcenac C, Magnard R, Goff LK, et al
    Reply to: Letter to the Editor by Martinez-Fernandez.
    Mov Disord. 2020;35:1084-1085.
    PubMed    


    May 2020
  517. NG J, Cortes-Saladelafont E, Abela L, Termsarasab P, et al
    DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.
    Mov Disord. 2020 May 30. doi: 10.1002/mds.28063.
    PubMed     Abstract available


  518. MULDERS AEP, van der Velden RMJ, Drukker M, Broen MPG, et al
    Usability of the Experience Sampling Method in Parkinson's Disease on a Group and Individual Level.
    Mov Disord. 2020 May 30. doi: 10.1002/mds.28028.
    PubMed     Abstract available


  519. HALL DA, Nag S, Ouyang B, Bennett DA, et al
    Fragile X Gray Zone Alleles Are Associated With Signs of Parkinsonism and Earlier Death.
    Mov Disord. 2020 May 28. doi: 10.1002/mds.28086.
    PubMed     Abstract available


  520. FABBRI M, Zibetti M, Rizzone MG, Giannini G, et al
    Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson's Disease?
    Mov Disord. 2020 May 25. doi: 10.1002/mds.28091.
    PubMed     Abstract available


  521. CILIA R, Bonvegna S, Straccia G, Nico GA, et al
    Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study.
    Mov Disord. 2020 May 25. doi: 10.1002/mds.28170.
    PubMed     Abstract available


  522. SHALASH A, Roushdy T, Essam M, Fathy M, et al
    Mental health, physical activity and quality of life in Parkinson's disease during COVID-19 pandemic.
    Mov Disord. 2020 May 19. doi: 10.1002/mds.28134.
    PubMed    


  523. TURNER TH, Dale ML
    Inconsistent Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Ratings in the Parkinson's Progression Marker Initiative.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28108.
    PubMed    


  524. MILOSEVIC L, Scherer M, Cebi I, Guggenberger R, et al
    Online Mapping with the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28093.
    PubMed     Abstract available


  525. MARRAS C, Pequeno P, Austin PC, Gershon AS, et al
    Beta Agonists and Progression of Parkinson's Disease in Older Adults: A Retrospective Cohort Study.
    Mov Disord. 2020 May 15. doi: 10.1002/mds.28085.
    PubMed    


  526. CHRISTINE CW, Auinger P, Saleh N, Tian M, et al
    Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression.
    Mov Disord. 2020 May 14. doi: 10.1002/mds.28073.
    PubMed     Abstract available


  527. CRAIG CE, Jenkinson NJ, Brittain JS, Grothe MJ, et al
    Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease.
    Mov Disord. 2020 May 13. doi: 10.1002/mds.28051.
    PubMed     Abstract available


  528. HATTORI N, Mochizuki H, Hasegawa K, Nomoto M, et al
    Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease.
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28071.
    PubMed     Abstract available


  529. BOIKA AV
    A postCOVID-19 parkinsonism in the future?
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28117.
    PubMed    


  530. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Can the 2019 novel coronavirus cause Parkinson's disease?
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28118.
    PubMed    


  531. SALARI M, Zali A, Ashrafi F, Etemadifar M, et al
    Incidence of Anxiety in Parkinson's Disease during Coronavirus disease (COVID-19) pandemic.
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28116.
    PubMed    


  532. BOOT E, Mentzel TQ, Palmer LD, van Harten PN, et al
    Age-Related Parkinsonian Signs in Microdeletion 22q11.2.
    Mov Disord. 2020 May 9. doi: 10.1002/mds.28080.
    PubMed     Abstract available


  533. SCHNEIDER SA, Alcalay RN
    Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
    Mov Disord. 2020 May 7. doi: 10.1002/mds.28072.
    PubMed    


  534. UCHIDA Y, Kan H, Sakurai K, Inui S, et al
    Magnetic Susceptibility Associates with Dopaminergic Deficits and Cognition in Parkinson's Disease.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28077.
    PubMed     Abstract available


  535. FAN SP, Lee NC, Lin CH
    Novel Phenotype of 6p25 Deletion Syndrome Presenting Juvenile Parkinsonism and Brain Calcification.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28079.
    PubMed     Abstract available


  536. PETERS S, Gallo V, Vineis P, Middleton LT, et al
    Alcohol Consumption and Risk of Parkinson's Disease: Data from a Large Prospective European Cohort.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28039.
    PubMed     Abstract available


  537. HORN MA, Gulberti A, Gulke E, Buhmann C, et al
    A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28083.
    PubMed     Abstract available


  538. HIRSCH EC, Standaert DG
    Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28075.
    PubMed     Abstract available


  539. TAKESHIGE-AMANO H, Saiki S, Fujimaki M, Ueno SI, et al
    Shared Metabolic Profile of Caffeine in Parkinsonian Disorders.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28068.
    PubMed     Abstract available


  540. ARCHER DB, Mitchell T, Burciu RG, Yang J, et al
    Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28060.
    PubMed     Abstract available


  541. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28052.
    PubMed     Abstract available


  542. BONET-PONCE PHD L, Cookson MR
    Can Leucine-Rich Repeat Kinase 2 Inhibition Benefit GBA-Parkinson's Disease?
    Mov Disord. 2020;35:721-723.
    PubMed    


  543. KIM HJ, Jeon B
    Does Urinary Retention Discriminate Multiple System Atrophy From Parkinson's Disease?
    Mov Disord. 2020;35:901-902.
    PubMed    


  544. CHAUDHURI KR, Jenner P, Antonini A
    Dyskinesia Matters: But Not as Much as It Used to.
    Mov Disord. 2020;35:900-901.
    PubMed    


  545. HAUSER RA, Eidelberg D, Pahwa R, Riggare S, et al
    Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini.
    Mov Disord. 2020;35:901.
    PubMed    


  546. FANCIULLI A, Wenning GK
    Which Autonomic Features Distinguish Multiple System Atrophy and When.
    Mov Disord. 2020;35:902-903.
    PubMed    


  547. ZHANG W, Yang C
    Stem Cell Modeling: A Promising New Avenue for Young-Onset PD Research.
    Mov Disord. 2020;35:759.
    PubMed    


    April 2020
  548. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Mov Disord. 2020 Apr 30. doi: 10.1002/mds.28066.
    PubMed     Abstract available


  549. GALOPPIN M, Berroir P, Soucy JP, Suzuki Y, et al
    Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography.
    Mov Disord. 2020 Apr 30. doi: 10.1002/mds.28046.
    PubMed     Abstract available


  550. WILSON H, Pagano G, de Natale ER, Mansur A, et al
    Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease.
    Mov Disord. 2020 Apr 29. doi: 10.1002/mds.28064.
    PubMed     Abstract available


  551. ANTONINI A, Leta V, Teo J, Chaudhuri KR, et al
    Outcome of Parkinson's Disease patients affected by COVID-19.
    Mov Disord. 2020 Apr 29. doi: 10.1002/mds.28104.
    PubMed    


  552. LOPEZ AM, Trujillo P, Hernandez AB, Lin YC, et al
    Structural Correlates of the Sensorimotor Cerebellum in Parkinson's Disease and Essential Tremor.
    Mov Disord. 2020 Apr 28. doi: 10.1002/mds.28044.
    PubMed     Abstract available


  553. WILKE C, Dos Santos MCT, Schulte C, Deuschle C, et al
    Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease.
    Mov Disord. 2020 Apr 27. doi: 10.1002/mds.28026.
    PubMed     Abstract available


  554. PRASAD S, Aguirre-Padilla DH, Poon YY, Kalsi-Ryan S, et al
    Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1-Year Prospective Trial.
    Mov Disord. 2020 Apr 20. doi: 10.1002/mds.28065.
    PubMed    


  555. PHILLIPPS C, Longato N, Bereau M, Carriere N, et al
    Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive-Compulsive Behavior? A Cross-Sectional Study.
    Mov Disord. 2020 Apr 20. doi: 10.1002/mds.28053.
    PubMed    


  556. PRASAD S, Holla VV, Neeraja K, Surisetti BK, et al
    Parkinson's disease and COVID-19: Perceptions and implications in patients and caregivers.
    Mov Disord. 2020 Apr 17. doi: 10.1002/mds.28088.
    PubMed    


  557. YOO JE, Jang W, Shin DW, Jeong SM, et al
    Timed Up and Go Test and the Risk of Parkinson's Disease: A Nation-wide Retrospective Cohort Study.
    Mov Disord. 2020 Apr 15. doi: 10.1002/mds.28055.
    PubMed     Abstract available


  558. HOPFNER F, Mueller SH, Szymczak S, Junge O, et al
    Rare Variants in Specific Lysosomal Genes Are Associated with Parkinson's Disease.
    Mov Disord. 2020 Apr 8. doi: 10.1002/mds.28037.
    PubMed     Abstract available


  559. OLANOW CW, Standaert DG, Kieburtz K, Viegas T, et al
    Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
    Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28027.
    PubMed     Abstract available


  560. PAPA SM, Brundin P, Fung VSC, Kang UJ, et al
    Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders.
    Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28067.
    PubMed    


  561. KARL JA, Ouyang B, Goetz S, Metman LV, et al
    A Novel DBS Paradigm for Axial Features in Parkinson's Disease: A Randomized Crossover Study.
    Mov Disord. 2020 Apr 4. doi: 10.1002/mds.28048.
    PubMed     Abstract available


    March 2020
  562. VIEIRA SRL, Toffoli M, Campbell P, Schapira AHV, et al
    Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy.
    Mov Disord. 2020 Mar 27. doi: 10.1002/mds.28030.
    PubMed    


  563. FEARON C, Farrell MA
    Disease-Specific Strains of alpha-Synuclein in Multiple System Atrophy and Parkinson's Disease: But Why?
    Mov Disord. 2020 Mar 23. doi: 10.1002/mds.28035.
    PubMed    


  564. SVENNINGSSON P, Odin P, Dizdar N, Johansson A, et al
    A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
    Mov Disord. 2020 Mar 21. doi: 10.1002/mds.28020.
    PubMed     Abstract available


  565. DONZUSO G, Agosta F, Canu E, Filippi M, et al
    MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
    Mov Disord. 2020 Mar 17. doi: 10.1002/mds.28025.
    PubMed     Abstract available


  566. LEODORI G, Belvisi D, De Bartolo MI, Fabbrini A, et al
    Re-emergent Tremor in Parkinson's Disease: The Role of the Motor Cortex.
    Mov Disord. 2020 Mar 16. doi: 10.1002/mds.28022.
    PubMed     Abstract available


  567. HIRATA K, Hattori T, Kina S, Chen Q, et al
    Striatal Dopamine Denervation Impairs Gait Automaticity in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Mar 12. doi: 10.1002/mds.28024.
    PubMed     Abstract available


  568. PALERMO G, Giannoni S, Frosini D, Morganti R, et al
    Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study.
    Mov Disord. 2020 Mar 10. doi: 10.1002/mds.28008.
    PubMed     Abstract available


  569. SHIN C, Lim Y, Lim H, Ahn TB, et al
    Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease.
    Mov Disord. 2020 Mar 10. doi: 10.1002/mds.28016.
    PubMed     Abstract available


  570. NUTT JG, Curtze C, Hiller A, Anderson S, et al
    Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.
    Mov Disord. 2020 Mar 9. doi: 10.1002/mds.27993.
    PubMed     Abstract available


  571. WIJEYEKOON RS, Moore SF, Farrell K, Breen DP, et al
    Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.
    Mov Disord. 2020 Mar 4. doi: 10.1002/mds.28015.
    PubMed     Abstract available


  572. MOOSA S, Martinez-Fernandez R, Elias WJ, Del Alamo M, et al
    Reply to: Comment on "the role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease".
    Mov Disord. 2020;35:521-522.
    PubMed    


  573. XU Y, He Q, Wang W
    Comment on "The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease".
    Mov Disord. 2020;35:521.
    PubMed    


  574. CASTILLO-TORRES SA, Sanchez-Cardenas M, Soto-Rincon CA, Chavez-Luevanos B, et al
    Kidney dysfunction and risk of Parkinson's disease: The issue of equations and large numbers.
    Mov Disord. 2020;35:519.
    PubMed    


  575. NAM GE, Kim NH, Han K, Choi KM, et al
    Reply to: Kidney Dysfunction and Risk of Parkinson's Disease: The Issue of Equations and Large Number".
    Mov Disord. 2020;35:520.
    PubMed    


  576. HANUSKA J, Rusz J, Bezdicek O, Dusek P, et al
    Comment on "pro-saccades predict cognitive decline in Parkinson's disease: ICICLE-PD".
    Mov Disord. 2020;35:522.
    PubMed    


    February 2020
  577. CHUNG SJ, Kim HR, Jung JH, Lee PH, et al
    Identifying the Functional Brain Network of Motor Reserve in Early Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28012.
    PubMed     Abstract available


  578. AMARA AW, Wood KH, Joop A, Memon RA, et al
    Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28009.
    PubMed     Abstract available


  579. ELFIL M, Kamel S, Kandil M, Koo BB, et al
    Implications of the Gut Microbiome in Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28004.
    PubMed     Abstract available


  580. WILLIAMS NM, Hubbard L, Sandor C, Webber C, et al
    Genome-Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor.
    Mov Disord. 2020 Feb 20. doi: 10.1002/mds.28001.
    PubMed    


  581. MIRELMAN A, Hillel I, Rochester L, Del Din S, et al
    Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease.
    Mov Disord. 2020 Feb 20. doi: 10.1002/mds.28006.
    PubMed     Abstract available


  582. SIMUNI T, Brumm MC, Uribe L, Caspell-Garcia C, et al
    Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Mov Disord. 2020 Feb 19. doi: 10.1002/mds.27989.
    PubMed     Abstract available


  583. SINGLETON AB, Gasser T
    The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease.
    Mov Disord. 2020 Feb 17. doi: 10.1002/mds.27999.
    PubMed    


  584. JAFARI Z, Kolb BE, Mohajerani MH
    Auditory Dysfunction in Parkinson's Disease.
    Mov Disord. 2020 Feb 13. doi: 10.1002/mds.28000.
    PubMed     Abstract available


  585. SEO SH, Bacolla A, Yoo D, Koo YJ, et al
    Replication-Based Rearrangements Are a Common Mechanism for SNCA Duplication in Parkinson's Disease.
    Mov Disord. 2020 Feb 10. doi: 10.1002/mds.27998.
    PubMed     Abstract available


  586. LITTLE S, Brown P
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020 Feb 10. doi: 10.1002/mds.27996.
    PubMed     Abstract available


  587. KNOX MG, Adler CH, Shill HA, Driver-Dunckley E, et al
    Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment.
    Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27991.
    PubMed     Abstract available


  588. POWELL A, Muller AJ, O'Callaghan C, Sourty M, et al
    Dopamine and Functional Connectivity in Patients With Parkinson's Disease and Visual Hallucinations.
    Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27995.
    PubMed    


  589. PINTER D, Janszky J, Kovacs N
    Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study".
    Mov Disord. 2020;35:375.
    PubMed    


  590. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study".
    Mov Disord. 2020;35:376-377.
    PubMed    


  591. FOLTYNIE T, Athauda D
    Diabetes, BMI, and Parkinson's.
    Mov Disord. 2020;35:201-203.
    PubMed    


  592. PALMA JA
    Renal dysfunction might be a marker of cardiovascular dysautonomia in prodromal alpha-synucleinopathies.
    Mov Disord. 2020;35:374.
    PubMed    


  593. MAHATO AK, Kopra J, Renko JM, Visnapuu T, et al
    Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
    Mov Disord. 2020;35:245-255.
    PubMed     Abstract available


  594. RAPPEL P, Grosberg S, Arkadir D, Linetsky E, et al
    Theta-alpha oscillations characterize emotional subregion in the human ventral subthalamic nucleus.
    Mov Disord. 2020;35:337-343.
    PubMed     Abstract available


  595. MARTINEZ E, Pasquereau B, Saga Y, Metereau E, et al
    The anterior caudate nucleus supports impulsive choices triggered by pramipexole.
    Mov Disord. 2020;35:296-305.
    PubMed     Abstract available


  596. LEE JY, Ahn J, Oh S, Shin JY, et al
    Retina thickness as a marker of neurodegeneration in prodromal lewy body disease.
    Mov Disord. 2020;35:349-354.
    PubMed     Abstract available


    January 2020
  597. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Pierre D. and the first photographs of Parkinson's disease.
    Mov Disord. 2020 Jan 24. doi: 10.1002/mds.27965.
    PubMed    


  598. GANG M, Baba T, Hosokai Y, Nishio Y, et al
    Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
    Mov Disord. 2020 Jan 23. doi: 10.1002/mds.27988.
    PubMed     Abstract available


  599. BARTH AL, Schneider JS, Johnston TH, Hill MP, et al
    NYX-458 improves cognitive performance in a primate Parkinson's disease model.
    Mov Disord. 2020 Jan 22. doi: 10.1002/mds.27962.
    PubMed     Abstract available


  600. IWAKI H, Blauwendraat C, Makarious MB, Bandres-Ciga S, et al
    Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score.
    Mov Disord. 2020 Jan 20. doi: 10.1002/mds.27974.
    PubMed     Abstract available


  601. VIJAYAN S, Singh B, Ghosh S, Stell R, et al
    Brainstem ventilatory dysfunction: A plausible mechanism for dyspnea in Parkinson's Disease?
    Mov Disord. 2020 Jan 15. doi: 10.1002/mds.27932.
    PubMed     Abstract available


  602. VACHEZ Y, Carcenac C, Magnard R, Kerkerian-Le Goff L, et al
    Subthalamic nucleus stimulation impairs motivation: Implication for apathy in Parkinson's disease.
    Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27953.
    PubMed     Abstract available


  603. SAMPEDRO F, Marin-Lahoz J, Martinez-Horta S, Perez-Gonzalez R, et al
    CLU rs11136000 promotes early cognitive decline in Parkinson's disease.
    Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27949.
    PubMed     Abstract available


  604. WIRTH T, Mariani LL, Bergant G, Baulac M, et al
    Loss-of-function mutations in NR4A2 cause dopa-responsive dystonia Parkinsonism.
    Mov Disord. 2020 Jan 10. doi: 10.1002/mds.27982.
    PubMed     Abstract available


  605. JI S, Wang C, Qiao H, Gu Z, et al
    Decreased Penetrance of Parkinson's Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study.
    Mov Disord. 2020 Jan 8. doi: 10.1002/mds.27971.
    PubMed     Abstract available


  606. RANGO M, Dossi G, Squarcina L, Bonifati C, et al
    Brain mitochondrial impairment in early-onset Parkinson's disease with or without PINK1 mutation.
    Mov Disord. 2020 Jan 2. doi: 10.1002/mds.27946.
    PubMed     Abstract available


  607. SANTOS-LOBATO BL, Schumacher-Schuh AF, Tumas V
    Predictors of Motor Complications in Early Parkinson's Disease.
    Mov Disord. 2020;35:191-192.
    PubMed    


  608. BAIG F, Kelly MJ, Lawton MA, Ben-Shlomo Y, et al
    Reply to: "Predictors of motor complications in early Parkinson's disease".
    Mov Disord. 2020;35:193.
    PubMed    


  609. KIM HJ, Mason S, Foltynie T, Winder-Rhodes S, et al
    Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort.
    Mov Disord. 2020;35:185-190.
    PubMed     Abstract available


  610. BELLOMO G, Paciotti S, Gatticchi L, Parnetti L, et al
    The vicious cycle between alpha-synuclein aggregation and autophagic-lysosomal dysfunction.
    Mov Disord. 2020;35:34-44.
    PubMed     Abstract available


  611. PYATIGORSKAYA N, Yahia-Cherif L, Gaurav R, Ewenczyk C, et al
    Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Mov Disord. 2020;35:161-170.
    PubMed     Abstract available


  612. COUGHLIN DG, Hurtig HI, Irwin DJ
    Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
    Mov Disord. 2020;35:5-19.
    PubMed     Abstract available


  613. CHAUDHURI KR, Schrag A, Weintraub D, Rizos A, et al
    The movement disorder society nonmotor rating scale: Initial validation study.
    Mov Disord. 2020;35:116-133.
    PubMed     Abstract available


  614. RESPONDEK G, Grimm MJ, Piot I, Arzberger T, et al
    Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
    Mov Disord. 2020;35:171-176.
    PubMed     Abstract available


  615. ALCALAY RN, Hsieh F, Tengstrand E, Padmanabhan S, et al
    Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Mov Disord. 2020;35:134-141.
    PubMed     Abstract available


    December 2019
  616. GENOUD S, Senior AM, Hare DJ, Double KL, et al
    Meta-analysis of copper and iron in Parkinson's disease brain and biofluids.
    Mov Disord. 2019 Dec 31. doi: 10.1002/mds.27947.
    PubMed     Abstract available


  617. SCHINDLBECK KA, Lucas-Jimenez O, Tang CC, Morbelli S, et al
    Metabolic network abnormalities in drug-naive Parkinson's Disease.
    Mov Disord. 2019 Dec 24. doi: 10.1002/mds.27960.
    PubMed     Abstract available


  618. WHITE RL 3RD, Campbell MC, Yang D, Shannon W, et al
    Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naive Parkinson's Disease.
    Mov Disord. 2019 Dec 19. doi: 10.1002/mds.27942.
    PubMed     Abstract available


  619. HALL S, Janelidze S, Zetterberg H, Brix B, et al
    Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.
    Mov Disord. 2019 Dec 13. doi: 10.1002/mds.27950.
    PubMed     Abstract available


  620. WANG Z, Yan J, Wang X, Yuan Y, et al
    Transcranial ultrasound stimulation directly influences the cortical excitability of the motor cortex in Parkinsonian mice.
    Mov Disord. 2019 Dec 12. doi: 10.1002/mds.27952.
    PubMed     Abstract available


  621. CRESSATTI M, Juwara L, Galindez JM, Velly AM, et al
    Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27935.
    PubMed     Abstract available


  622. MONJE MHG, Blesa J, Garcia-Cabezas MA, Obeso JA, et al
    Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27921.
    PubMed     Abstract available


  623. RAVANIDIS S, Bougea A, Papagiannakis N, Maniati M, et al
    Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27928.
    PubMed     Abstract available


  624. COSENTINO C, Baccini M, Putzolu M, Ristori D, et al
    Effectiveness of Physiotherapy on Freezing of Gait in Parkinson's Disease: A Systematic Review and Meta-Analyses.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27936.
    PubMed     Abstract available


  625. NEVES MA, Bouca-Machado R, Guerreiro D, Canica V, et al
    Swimming Is Compromised in Parkinson's Disease Patients.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27918.
    PubMed     Abstract available


  626. DE LA CASA-FAGES B, Fernandez-Eulate G, Gamez J, Barahona-Hernando R, et al
    Reply to: "Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion".
    Mov Disord. 2019;34:1932-1933.
    PubMed    


  627. REDDY SP, Socal MP, Rieder CRM, Schumacher-Schuh AF, et al
    Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens.
    Mov Disord. 2019;34:1929-1930.
    PubMed    


  628. CHAUDHURI KR, Jenner P, Antonini A
    Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens".
    Mov Disord. 2019;34:1930-1931.
    PubMed    


  629. FINSTERER J
    Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion.
    Mov Disord. 2019;34:1931-1932.
    PubMed    


  630. OBESO JA
    Editor's Note: Deep Brain Stimulation and Functional Neurosurgery for Movement Disorders: Is the Current Cycle Waning?
    Mov Disord. 2019;34:1792-1794.
    PubMed    


    November 2019
  631. LOPEZ G, Steward A, Ryan E, Groden C, et al
    Clinical Evaluation of Sibling Pairs With Gaucher Disease Discordant for Parkinsonism.
    Mov Disord. 2019 Nov 30. doi: 10.1002/mds.27916.
    PubMed     Abstract available


  632. JEONG SM, Han K, Kim D, Rhee SY, et al
    Body mass index, diabetes, and the risk of Parkinson's disease.
    Mov Disord. 2019 Nov 30. doi: 10.1002/mds.27922.
    PubMed     Abstract available


  633. MORALES-BRICENO H, Fung VSC
    Enhancement of glycolysis: A potential disease-modifying strategy for Parkinson's disease.
    Mov Disord. 2019 Nov 29. doi: 10.1002/mds.27934.
    PubMed    


  634. DELGADO-ALVARADO M, Marano M, Santurtun A, Urtiaga-Gallano A, et al
    Nonpharmacological, Nonsurgical Treatments for Freezing of Gait in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2019 Nov 26. doi: 10.1002/mds.27913.
    PubMed     Abstract available


  635. KIM IY, Yang TO, Heath AK, Simpson RF, et al
    Alcohol intake and Parkinson's disease risk in the million women study.
    Mov Disord. 2019 Nov 26. doi: 10.1002/mds.27933.
    PubMed     Abstract available


  636. BETROUNI N, Lopes R, Defebvre L, Leentjens AFG, et al
    Texture features of magnetic resonance images: A marker of slight cognitive deficits in Parkinson's disease.
    Mov Disord. 2019 Nov 23. doi: 10.1002/mds.27931.
    PubMed     Abstract available


  637. MANNE S, Kondru N, Jin H, Anantharam V, et al
    alpha-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients.
    Mov Disord. 2019 Nov 23. doi: 10.1002/mds.27907.
    PubMed     Abstract available


  638. BARBE MT, Tonder L, Krack P, Debu B, et al
    Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications.
    Mov Disord. 2019 Nov 22. doi: 10.1002/mds.27892.
    PubMed     Abstract available


  639. DI CAPRIO V, Modugno N, Mancini C, Olivola E, et al
    Early-stage Parkinson's patients show selective impairment in reactive but not proactive inhibition.
    Mov Disord. 2019 Nov 21. doi: 10.1002/mds.27920.
    PubMed     Abstract available


  640. BAIANO C, Barone P, Trojano L, Santangelo G, et al
    Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: A meta-analysis.
    Mov Disord. 2019 Nov 19. doi: 10.1002/mds.27902.
    PubMed     Abstract available


  641. MERTSALMI TH, Pekkonen E, Scheperjans F
    Antibiotic exposure and risk of Parkinson's disease in finland: A nationwide case-control study.
    Mov Disord. 2019 Nov 18. doi: 10.1002/mds.27924.
    PubMed     Abstract available


  642. OOSTERVELD LP, Verberk IMW, Majbour NK, El-Agnaf OM, et al
    CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson's from controls.
    Mov Disord. 2019 Nov 18. doi: 10.1002/mds.27897.
    PubMed     Abstract available


  643. PAZ-ALONSO PM, Navalpotro-Gomez I, Boddy P, Dacosta-Aguayo R, et al
    Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27885.
    PubMed     Abstract available


  644. SIDRANSKY E, Arkadir D, Bauer P, Dinur T, et al
    Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse?
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27903.
    PubMed    


  645. FANCIULLI A, Goebel G, Lazzeri G, Granata R, et al
    Urinary retention discriminates multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27917.
    PubMed    


  646. GILBERT RM, Standaert DG
    Bridging the gaps: More inclusive research needed to fully understand Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27906.
    PubMed    


  647. GAJOS KZ, Reinecke K, Donovan M, Stephen CD, et al
    Computer Mouse Use Captures Ataxia and Parkinsonism, Enabling Accurate Measurement and Detection.
    Mov Disord. 2019 Nov 7. doi: 10.1002/mds.27915.
    PubMed     Abstract available


  648. LAWTON M, Baig F, Toulson G, Morovat A, et al
    Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort.
    Mov Disord. 2019 Nov 6. doi: 10.1002/mds.27888.
    PubMed     Abstract available


  649. PETRILLO S, Schirinzi T, Di Lazzaro G, D'Amico J, et al
    Systemic activation of Nrf2 pathway in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27878.
    PubMed     Abstract available


  650. HAQUE ME, Akther M, Jakaria M, Kim IS, et al
    Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27874.
    PubMed     Abstract available


  651. RAJPUT AH, Rajput EF, Bocking SM, Auer RN, et al
    Reply to: Parkinsonism in essential tremor cases: A clinicopathological study-were they really essential tremor?
    Mov Disord. 2019;34:1750.
    PubMed    


  652. DE PEDRO-CUESTA J, Martinez-Martin P, Calero M, Almazan-Isla J, et al
    Reconciling etiological views on Parkinson's disease.
    Mov Disord. 2019;34:1750-1752.
    PubMed    


  653. MULROY E, Latorre A, Bhatia KP
    Parkinsonism in essential tremor cases: A clinicopathological study-were they really essential tremor?
    Mov Disord. 2019;34:1749.
    PubMed    


  654. RUNDEK T, Shpiner DS, Margolesky J
    Perivascular spaces in basal ganglia - An innocent bystander in Parkinson's disease?
    Mov Disord. 2019;34:1585-1587.
    PubMed    


    October 2019
  655. GILAT M, Coeytaux Jackson A, Marshall NS, Hammond D, et al
    Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Randomised Controlled Trial.
    Mov Disord. 2019 Oct 31. doi: 10.1002/mds.27886.
    PubMed     Abstract available


  656. LERCHE S, Wurster I, Roeben B, Zimmermann M, et al
    Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles.
    Mov Disord. 2019 Oct 30. doi: 10.1002/mds.27884.
    PubMed     Abstract available


  657. BANDRES-CIGA S, Ahmed S, Sabir MS, Blauwendraat C, et al
    The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight.
    Mov Disord. 2019 Oct 29. doi: 10.1002/mds.27864.
    PubMed     Abstract available


  658. NOYCE AJ, Bandres-Ciga S, Kim J, Heilbron K, et al
    The Parkinson's Disease Mendelian Randomization Research Portal.
    Mov Disord. 2019 Oct 28. doi: 10.1002/mds.27873.
    PubMed     Abstract available


  659. HAYAKAWA H, Nakatani R, Ikenaka K, Aguirre C, et al
    Structurally distinct alpha-synuclein fibrils induce robust parkinsonian pathology.
    Mov Disord. 2019 Oct 23. doi: 10.1002/mds.27887.
    PubMed     Abstract available


  660. PRETEGIANI E, Vanegas-Arroyave N, FitzGibbon EJ, Hallett M, et al
    Evidence From Parkinson's Disease That the Superior Colliculus Couples Action and Perception.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27861.
    PubMed     Abstract available


  661. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27876.
    PubMed     Abstract available


  662. MORALES-BRICENO H, Mahant N, Ha AD, Chang FCF, et al
    Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27883.
    PubMed    


  663. KOLMANCIC K, Perellon-Alfonso R, Pirtosek Z, Rothwell JC, et al
    Sex differences in Parkinson's disease: A transcranial magnetic stimulation study.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27870.
    PubMed     Abstract available


  664. VAN DER VEEN S, Zutt R, Klein C, Marras C, et al
    Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27828.
    PubMed     Abstract available


  665. SACHELI MA, Neva JL, Lakhani B, Murray DK, et al
    Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27865.
    PubMed     Abstract available



  666. Abstracts of the 2019 International Congress of the Parkinson's Disease and Movement Disorders(R).
    Mov Disord. 2019;34 Suppl 2:S1-S930.
    PubMed    


  667. HONKANEN EA, Saari L, Orte K, Gardberg M, et al
    Reply to: The time delay between in vivo imaging and postmortem data poses a caveat on "no link" findings.
    Mov Disord. 2019;34:1580-1581.
    PubMed    


  668. PIFL C
    The time delay between in vivo imaging and postmortem data poses a caveat on "no link" findings.
    Mov Disord. 2019;34:1579-1580.
    PubMed    


    September 2019
  669. BOUTHOUR W, Bereau M, Kibleur A, Zacharia A, et al
    Dyskinesia-inducing lead contacts optimize outcome of subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27853.
    PubMed     Abstract available


  670. DAYAL V, Grover T, Tripoliti E, Milabo C, et al
    Short Versus Conventional Pulse-Width Deep Brain Stimulation in Parkinson's Disease: A Randomized Crossover Comparison.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27863.
    PubMed     Abstract available


    July 2019
  671. MORALES-BRICENO H, Fung VSC
    You shall not pass! Gut bacteria can convert levodopa to dopamine.
    Mov Disord. 2019;34:986.
    PubMed    


  672. LATORRE A, Rocchi L, Berardelli A, Bhatia KP, et al
    The interindividual variability of transcranial magnetic stimulation effects: Implications for diagnostic use in movement disorders.
    Mov Disord. 2019;34:936-949.
    PubMed     Abstract available


  673. HINKLE JT, Dawson VL, Dawson TM
    The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.
    Mov Disord. 2019;34:959-969.
    PubMed     Abstract available


  674. KRISMER F, Seppi K, Gobel G, Steiger R, et al
    Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis.
    Mov Disord. 2019;34:1041-1048.
    PubMed     Abstract available


    June 2019
  675. OLANOW CW
    Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less.
    Mov Disord. 2019;34:812-815.
    PubMed    


    May 2019
  676. LI J, Dauer W
    Cholinergic interneurons drive maladaptive changes in thalamostriatal circuitry after dopamine depletion.
    Mov Disord. 2019;34:682.
    PubMed    


    April 2019
  677. KISHORE A, Ashok Kumar Sreelatha A, Sturm M, von-Zweydorf F, et al
    Understanding the role of genetic variability in LRRK2 in Indian population.
    Mov Disord. 2019;34:496-505.
    PubMed     Abstract available


    March 2019
  678. BREEN DP, Halliday GM, Lang AE
    Gut-brain axis and the spread of alpha-synuclein pathology: Vagal highway or dead end?
    Mov Disord. 2019;34:307-316.
    PubMed     Abstract available


  679. ARENS J, Storzer L, Hirschmann J, Dalal SS, et al
    Freezing of gait does not modulate beta oscillations in mesial cortical motor areas.
    Mov Disord. 2019;34:436.
    PubMed    


    February 2019
  680. ROSS GW, Abbott RD, Petrovitch H, Duda JE, et al
    Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology.
    Mov Disord. 2019;34:228-235.
    PubMed     Abstract available


  681. SEBILLE SB, Rolland AS, Faillot M, Perez-Garcia F, et al
    Normal and pathological neuronal distribution of the human mesencephalic locomotor region.
    Mov Disord. 2019;34:218-227.
    PubMed     Abstract available


    January 2019
  682. HOMAYOON N, Pirpamer L, Franthal S, Katschnig-Winter P, et al
    Nigral iron deposition in common tremor disorders.
    Mov Disord. 2019;34:129-132.
    PubMed     Abstract available


  683. WHITWELL JL, Tosakulwong N, Schwarz CG, Botha H, et al
    MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.
    Mov Disord. 2019;34:105-113.
    PubMed     Abstract available


  684. HARRIS M, Steele J, Williams R, Pinkston J, et al
    MRI-guided laser interstitial thermal thalamotomy for medically intractable tremor disorders.
    Mov Disord. 2019;34:124-129.
    PubMed     Abstract available


  685. FISCHER DL, Sortwell CE
    BDNF provides many routes toward STN DBS-mediated disease modification.
    Mov Disord. 2019;34:22-34.
    PubMed     Abstract available


  686. HARMSEN IE, Lee DJ, Dallapiazza RF, De Vloo P, et al
    Ultra-high-frequency deep brain stimulation at 10,000 Hz improves motor function.
    Mov Disord. 2019;34:146-148.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: